MXPA99001454A - Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles - Google Patents
Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazolesInfo
- Publication number
- MXPA99001454A MXPA99001454A MXPA/A/1999/001454A MX9901454A MXPA99001454A MX PA99001454 A MXPA99001454 A MX PA99001454A MX 9901454 A MX9901454 A MX 9901454A MX PA99001454 A MXPA99001454 A MX PA99001454A
- Authority
- MX
- Mexico
- Prior art keywords
- hydrogen
- halogen
- carbon atoms
- alkyl
- substituents
- Prior art date
Links
- 150000002337 glycosamines Chemical class 0.000 title abstract description 4
- 230000001472 cytotoxic Effects 0.000 title description 3
- 231100000433 cytotoxic Toxicity 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 65
- -1 substituents halogen Chemical class 0.000 claims description 63
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 59
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 37
- 150000002367 halogens Chemical class 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 229910052757 nitrogen Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 230000000259 anti-tumor Effects 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000005418 aryl aryl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000005842 heteroatoms Chemical group 0.000 claims description 4
- 125000000625 hexosyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000002829 nitrogen Chemical group 0.000 claims description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 7
- CFIWXQDRNFECMZ-UHFFFAOYSA-N 5-(2-bromophenyl)-1,2-oxazole Chemical compound BrC1=CC=CC=C1C1=CC=NO1 CFIWXQDRNFECMZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001805 pentosyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 197
- 239000000203 mixture Substances 0.000 description 98
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- 239000007787 solid Substances 0.000 description 88
- 239000000243 solution Substances 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 63
- IOLCXVTUBQKXJR-UHFFFAOYSA-M Potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 46
- 239000012267 brine Substances 0.000 description 40
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000003818 flash chromatography Methods 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 238000001819 mass spectrum Methods 0.000 description 29
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 28
- LJFIPVIYARKJOQ-UHFFFAOYSA-N carbazole-2,4-dione Chemical compound C1=CC=CC2=NC3=CC(=O)CC(=O)C3=C21 LJFIPVIYARKJOQ-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- COMOCXIDWDXEDQ-UHFFFAOYSA-N C12=CN=CC2=CC(=O)C2=C1C1=CC=CC(=O)C1=N2 Chemical compound C12=CN=CC2=CC(=O)C2=C1C1=CC=CC(=O)C1=N2 COMOCXIDWDXEDQ-UHFFFAOYSA-N 0.000 description 25
- 102000003915 DNA Topoisomerases Human genes 0.000 description 24
- 108090000323 DNA Topoisomerases Proteins 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000008079 hexane Substances 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 238000010992 reflux Methods 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000010265 fast atom bombardment Methods 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 101700067048 CDC13 Proteins 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000012299 nitrogen atmosphere Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 239000012300 argon atmosphere Substances 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000010828 elution Methods 0.000 description 16
- 210000004027 cells Anatomy 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000001544 thienyl group Chemical group 0.000 description 15
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 14
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- LMYWWPCAXXPJFF-UHFFFAOYSA-P Cornforth reagent Chemical compound C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O LMYWWPCAXXPJFF-UHFFFAOYSA-P 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940054051 antipsychotic Indole derivatives Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical compound C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000001184 potassium carbonate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 229910052904 quartz Inorganic materials 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1H-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 2
- 102100003470 CHAT Human genes 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N Deuterated acetone Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KOSYAAIZOGNATQ-UHFFFAOYSA-N O-phenyl chloromethanethioate Chemical compound ClC(=S)OC1=CC=CC=C1 KOSYAAIZOGNATQ-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N Pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N Tributyltin hydride Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000269 nucleophilic Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 101710004466 rgy Proteins 0.000 description 2
- 101710030364 rgy1 Proteins 0.000 description 2
- 101710030359 rgy2 Proteins 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HWBIQJOWCBKZJW-UHFFFAOYSA-N $l^{1}-silanyloxysilicon Chemical compound [Si]O[Si] HWBIQJOWCBKZJW-UHFFFAOYSA-N 0.000 description 1
- MXYLLYBWXIUMIT-PFBJBMPXSA-N (2R,3S,4R)-3,4-bis(phenylmethoxy)-2-(phenylmethoxymethyl)-3,4-dihydro-2H-pyran Chemical compound C([C@@H]1[C@H]([C@H](OCC=2C=CC=CC=2)C=CO1)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 MXYLLYBWXIUMIT-PFBJBMPXSA-N 0.000 description 1
- OGOMAWHSXRDAKZ-BKJHVTENSA-N (3R,4S,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-ol Chemical compound C([C@H]1OC([C@@H]([C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)O)OCC1=CC=CC=C1 OGOMAWHSXRDAKZ-BKJHVTENSA-N 0.000 description 1
- ZGXVRSDFOPQNKL-CMLBZCPWSA-N (3S,4S,5R,6R)-3-fluoro-4,5-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxane-2,3-diol Chemical compound C([C@H]1OC([C@@]([C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)(O)F)O)OCC1=CC=CC=C1 ZGXVRSDFOPQNKL-CMLBZCPWSA-N 0.000 description 1
- HSUNOBHQLAOKKH-AATRIKPKSA-N (E)-2-(4-fluoro-2-nitrophenyl)-N,N-dimethylethenamine Chemical compound CN(C)\C=C\C1=CC=C(F)C=C1[N+]([O-])=O HSUNOBHQLAOKKH-AATRIKPKSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- MEZJQXVOMGUAMP-UHFFFAOYSA-N 1-(2-methylnaphthalen-1-yl)pyrrole-2,5-dione Chemical group CC1=CC=C2C=CC=CC2=C1N1C(=O)C=CC1=O MEZJQXVOMGUAMP-UHFFFAOYSA-N 0.000 description 1
- QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- FCAJYRVEBULFKS-UHFFFAOYSA-N 2-(oxolan-2-yl)ethanol Chemical compound OCCC1CCCO1 FCAJYRVEBULFKS-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- ZTXGHULWOWPBOK-UHFFFAOYSA-N 3-bromo-4-(6-fluoro-1H-indol-3-yl)pyrrole-2,5-dione Chemical compound C=1NC2=CC(F)=CC=C2C=1C1=C(Br)C(=O)NC1=O ZTXGHULWOWPBOK-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006491 4-t-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 229940040526 Anhydrous Sodium Acetate Drugs 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- YZPSXQVQCYSZTO-UHFFFAOYSA-N C12=NC3=CC=CC=C3C2=C2C(=O)NC(=O)C2=C2C1=NC1=CC=CC=C12 Chemical compound C12=NC3=CC=CC=C3C2=C2C(=O)NC(=O)C2=C2C1=NC1=CC=CC=C12 YZPSXQVQCYSZTO-UHFFFAOYSA-N 0.000 description 1
- XYSJOYPMIAWCHK-PSKHUYHASA-N C1=CC(C(C)(C)C)=CC=C1CN1C(=O)C(C=2C(N([C@H]3[C@@H]([C@@H](OCC=4C=CC=CC=4)C[C@@H](COCC=4C=CC=CC=4)O3)OCC=3C=CC=CC=3)[C]3C=C(F)C(F)=CC3=2)=C2C3=C4[CH]C(F)=C(F)C=C4N2)=C3C1=O Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1C(=O)C(C=2C(N([C@H]3[C@@H]([C@@H](OCC=4C=CC=CC=4)C[C@@H](COCC=4C=CC=CC=4)O3)OCC=3C=CC=CC=3)[C]3C=C(F)C(F)=CC3=2)=C2C3=C4[CH]C(F)=C(F)C=C4N2)=C3C1=O XYSJOYPMIAWCHK-PSKHUYHASA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 101700010918 CPP1 Proteins 0.000 description 1
- AUPXBVDHVRZMIB-UHFFFAOYSA-M C[Mg]I Chemical compound C[Mg]I AUPXBVDHVRZMIB-UHFFFAOYSA-M 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M Caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- TYNQWWGVEGFKRU-AJDPQWBVSA-N Chaconine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O TYNQWWGVEGFKRU-AJDPQWBVSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-SVYQBANQSA-N Deuterated THF Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N Disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 108010058699 EC 2.3.1.6 Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N Ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N Isoamyl alcohol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- MPVYUOZJQRVUGW-UHFFFAOYSA-N N1C=CC2=CC=CC=C12.C1=CN=C2C=CC3=C4C=CC=CC4=NC3=C21 Chemical class N1C=CC2=CC=CC=C12.C1=CN=C2C=CC3=C4C=CC=CC4=NC3=C21 MPVYUOZJQRVUGW-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- QADZFATVRYZXDJ-QCUUGYDUSA-N NN1C(C=2C3=C(C=4NC5=CC(=CC=C5C=4C=2C1=O)F)N(C=1C=C(C=CC=13)F)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CN)=O Chemical compound NN1C(C=2C3=C(C=4NC5=CC(=CC=C5C=4C=2C1=O)F)N(C=1C=C(C=CC=13)F)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CN)=O QADZFATVRYZXDJ-QCUUGYDUSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- RPJHCCBSXJXYHN-QCUUGYDUSA-N O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=C3NC4=CC(F)=C(F)C=C4C3=C3C(=O)NC(=O)C3=C2C2=CC(F)=C(F)C=C21 Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=C3NC4=CC(F)=C(F)C=C4C3=C3C(=O)NC(=O)C3=C2C2=CC(F)=C(F)C=C21 RPJHCCBSXJXYHN-QCUUGYDUSA-N 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 101710027499 Os03g0268000 Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M Potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 241000701550 Pseudoalteromonas virus PM2 Species 0.000 description 1
- 241000204098 Saccharothrix Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- IGELFKKMDLGCJO-UHFFFAOYSA-N Xenon difluoride Chemical compound F[Xe]F IGELFKKMDLGCJO-UHFFFAOYSA-N 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-O azanium;ethanol Chemical compound [NH4+].CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-O 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CGAMNSKIHXUDMK-UHFFFAOYSA-N benzyl N-[methylsulfanyl(phenylmethoxycarbonylamino)methylidene]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N=C(SC)NC(=O)OCC1=CC=CC=C1 CGAMNSKIHXUDMK-UHFFFAOYSA-N 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 101700052859 cdf-1 Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 101700028937 chrR Proteins 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical class CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- FQKSBRCHLNOAGY-UHFFFAOYSA-N indolo[2,3-a]carbazole Chemical compound C1=CC=C2N=C3C4=NC5=CC=CC=C5C4=CC=C3C2=C1 FQKSBRCHLNOAGY-UHFFFAOYSA-N 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- FELGDWYLIIVCRC-UHFFFAOYSA-N oxolan-2-ylmethanol;hydrate Chemical compound O.OCC1CCCO1 FELGDWYLIIVCRC-UHFFFAOYSA-N 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- MZFXHSQFQLKKFD-UHFFFAOYSA-M potassium;fluoride;dihydrate Chemical compound O.O.[F-].[K+] MZFXHSQFQLKKFD-UHFFFAOYSA-M 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-M pyridine;chloride Chemical compound [Cl-].C1=CC=NC=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-M 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical class N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 description 1
- GAAWKLUURLVNGE-UHFFFAOYSA-N pyrrolo[3,4-c]carbazole Chemical compound C1=CC=C2C3=C4C=NC=C4C=CC3=NC2=C1 GAAWKLUURLVNGE-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 description 1
- STMPXDBGVJZCEX-UHFFFAOYSA-N triethylsilyl trifluoromethanesulfonate Chemical compound CC[Si](CC)(CC)OS(=O)(=O)C(F)(F)F STMPXDBGVJZCEX-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JNEZJAAADKQBBD-UHFFFAOYSA-N tris(2-chlorophenyl) borate Chemical compound ClC1=CC=CC=C1OB(OC=1C(=CC=CC=1)Cl)OC1=CC=CC=C1Cl JNEZJAAADKQBBD-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Abstract
The present invention concerns novel amino sugar and related sugar derivatives of indolopyrrolocarbazoles, their use as antitumor agents, and pharmaceutical formulations.
Description
/ /
AMINOAZÚCAR CITOTÓXICA AND DERIVADOS DE AZÚCAR RELATED OF INDOLOPIRROLOCARBAZOLES
I. Field of the Invention
The present invention relates to ammoazucar and other sugar derivatives of indolopyrrolocarbazoles, their salts and hydrates, some of which compounds show topoisomerase I activity, which are useful for inhibiting the proliferation of tumor cells, are useful in showing antitumor effect, and a process for preparing them.
II. Description of the Previous Technique
The alkaloids of indole [2, 3-a] carbazole such as rebeccamycin (US Patents Nos. 4.46"7.925 and 4.552.642) and its clinically active analogue, soluble in water, the 6- (2-diethylamethyl) rebeccamycin ( 1) (U.S. Patent No. 4,785,085) are useful antimicrobial agents which target DNA.
REF. 29231
The topoisos erasas are vital nuclear enzymes which work to solve the topological dilemmas in the DNA, such as overenrolment, unwinding and concatenation, which normally arise during replication, transcription and perhaps during other DNA processes. These enzymes allow the DNA to relax by forming strand breaks with enzymatic bridges that act as transient bridges or as pivot points for the passage of other strands of DNA. Drugs that target the topoisomerase appear to interfere with this break-reunion reaction of the DNA topoisomerases. In the presence of topoisomerase active agents, an aborted reaction intermediate called "cleavable complex" accumulates and results in the arrest of replication / transcription which ultimately leads to cell death. The development of topoisomerase I active agents, therefore, offers a new procedure for the arsenal of multiple regimen therapies currently used in clinics for the treatment of cancer. The article in Cancer Chemother. Pharmacol (1994), 34 (suppl): S 41-S 45 discusses the active compounds of topoisomerase I that are in clinical studies and it is found that these agents are effective in clinical antitumor studies. Naturally, these clinical candidates are related to the alkaloid Camptothecin (2).
Camptothecin The publications of European Patent Application 0,545,195 Bl published on November 22, 1995 and 0,602,597 A2 published on June 22, 1994 and in Cancer Research 1993, 5_3, 490-494 and 1995, 55, 1310-1315 described the derivatives ( 3) of indolo [2,3-a] -carbazole related to the class of rebeccamycin and claimed antitumor activity; however, the major mechanism of action may not be similar to camptothecin. The camptothecins act by the mechanism of topoisomerase I. International Patent Application WO 95/30682 also described the molodocarbazoles related to compound (3) and claimed antitumor activity.
Hudkins et al. In International Patent Application W096 / 11933 published April 25, 1996 and its corresponding US Patent No. 5,475,110 described a series of fused pyrrolocarbazoles and displayed in vitro biological data such as the inhibition of neuronal choline acetyltransferase ( ChAT), the inhibition of protein kinase C (PKC) for some compounds. U.S. Patent No. 5,468,849 discloses certain fluororrebecamycin analogs as useful anti-tumor agents, together with a process for their production by feeding the f luorotripytophan analog of a strain of Sacchdrothrix aerocolonigenes that produces rebeccamycin, preferably Saccharothrix aerocclomgenes C38,383 -RK2 (ATCC 39243). Glicksman and co-workers in the North American Patent No. 5,468,872 disclose the indolocarbazole alkaloids which are different in structure from those of the formula I of the present invention. Kojiri et al. In International Application WO96 / 04293 published February 15, 1996 discloses the mdolopyrrolocarbazoles having a disaccharide substituent which is different from the present amino substituted sugar compounds. There is nothing in any of the above references, or in the general prior art, which suggests the novel cytotoxic amino sugar and other sugar derivatives of indole pyrrolocarbazoles, some of which are topoisomerase I active agents, of the present invention.
BRIEF DESCRIPTION OF THE INVENTION
An object of the present invention is to provide the new sugar derivatives of the polyolcarboxyles which inhibit the. proliferation of the antitumor cells and some of the derivatives show increased solubility in water, and topoisomerase I activity. This invention relates to the novel animal compounds represented by the formula. I, or a pharmaceutically acceptable salt of the isms
wherein: R. and R.β are independently hydrogen, a pentose group (A) or a hexose group (B) of the formulas
with the proviso that one of R- and R: ß is hydrogen and the other is not hydrogen; R, R, R, R. and R., R. ,, R .., R ... and R, are independently hydrogen, alkyl of 1 to 7 carbon atoms, cycloalkyl of 1 to 7 carbon atoms, OR , azido, halogen, NR9R10. NHC (0) NR9R10. NHC (0) 0R, OR, -C (0) Ra, SR, -OS02Rc > or together they form = N-0H, = 0, = NR, with the proviso that R2, R3, R4, R5 and R2-, R3., R4-, R? ", and R5 'are not all simultaneously hydrogen, OH , alkoxy or alkyl, and with the proviso further that R3 or R.- is not -NH2, except when R6 is - (CH) .NHC (= NH) NH, said alkyl of 1 to 7 carbon atoms is optionally substituted with one to six of the same or different substituents halogen, CN, NO;, aryl or heteroaryl, the aryl or heteroaryl substituted with one or two groups independently selected from NRaR.o, OH, C00R9, SO R, SO R or OCOR R is H, OH, alkoxy of 1 to 7 carbon atoms or NR R, R is alkyl of 1 to 7 carbon atoms or aryl, R and R .. are independently hydrogen, alkyl of 1 to 7 carbon atoms , cycloalkyl of 1 to 7 carbon atoms, heteroapium, ring of 5 to 8 members, cyclic, non-aromatic, containing either one or two heteroatoms selected from oxygen or nitrogen, (CH.). NR.R;, (CH; ) -OR-. O { CH:). COOR-. , the alkyl of 1 to 7 carbon atoms is optionally substituted with one to six of the same or different halogen, OH, CN, NO, aryl or heteroaryl substituents, the aryl or the heteroaryl are substituted with one or two independently selected groups of NR9R? 0, OH, COOR ?, S03R9 or OCOR9; R <0> and R <10> are independently hydrogen, alkyl of 1 to 7 carbon atoms, cycloalkyl of 1 to 7 carbon atoms, benzyl, aryl, heteroaryl, any of which groups except hydrogen may be substituted with one to six thereof or different substituents halogen, OH, NH2, CN, N02, -C (= NH) NH2, 0 -CH (= NH), CH (Rc) (CH.) - COOH or CH (Rb) (CH2) nNH2 or COOR. ., or R and R. together with the nitrogen atom to which they are attached, form a cyclic 5- to 8-membered non-aromatic ring, containing either one or two heteroatoms of oxygen, nitrogen or sulfur, or R9 and - R with just form = CHRR -.- .. R. is H or COOH; R is hydrogen, alkyl of 1 to 7 carbon atoms, aplo, aplaxyl, OR, NR.R-. , or OCO (CHr) r.NR_R :,, the alkyl of 1 to 7 carbon atoms is optionally substituted with one to six of the same or different substituents halogen, NR ^ R; , CN, N02, aryl, the aryl is substituted with one or two groups independently selected from NR.Ri-j, OH, COORo, SO R or OCOR;
R-? and R8 are independently OH or hydrogen, or taken together is oxygen; X :, X'i, X2 and X'2 are independently hydrogen, halogen, OH, -CN, -NC, CF3, -CORa, N02, OR, 0 (CH2) -NRoR10, 0 (CH2) nORa or O ( CH2) nCOOR9; with the proviso that X;, X'2, X. and X '. Do not be 1,11-dichloro; with the additional condition that when X2 and X '; are each hydrogen, X: and X'_ are each independently hydrogen or halogen, R. is hexose, R- and Rt together are oxygen, and each of R.-, R ?, and R4 are OH, R2- , R2-, R4-, and R5. and Rosean each hydrogen, Q is NH, and then each of R. and R; do not be NH; and R3 is not methoxy when R is heterogeneous; W is carbon or nitrogen; C is oxygen, NR, sulfur or CH; and r. is an integer from 0 to 4. Yet another aspect of the present invention provides a method for inhibiting tumor growth in a mammalian host, which comprises administering to said host an amount that inhibits the tumor growth of a compound of the formula
Yet another aspect of the present invention provides a pharmaceutical formulation comprising an effective anti-tumor amount of a compound of the formula I in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides the novel amino sugar and related derivatives of the dipopyrrolocarbazoles and salts thereof, some of which are topoisomerase I active agents. These compounds are useful for inhibiting the proliferation of antitumor cells and show antitumor effect. In the request, unless explicitly specified otherwise or in the context, the following definitions apply. The numbers in the subscript after the "C" symbol define the number of carbon atoms that a particular group can contain. For example "alkyl C: -." (alkyl of 1 to 6 carbon atoms) means a saturated, linear or branched carbon chain having from one to six carbon atoms; examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, sec-pentyl, isopentyl and n-hexyl. Depending on the context "alkyl of 1 to 6 carbon atoms" can also refer to alkylene of 1 to 6 carbon atoms which bridges two groups; examples include 5-propan-1,3-diyl, butan- ?, 4-diyl, 2-methyl-butan-1, 4-diyl, etc. "C2 -C6 alkenyl" means a straight or branched carbon chain having at least one carbon-carbon double bond, and having from two to six carbon atoms; the 0 examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl. Depending on the context, "alkenyl of 2 to 6 carbon atoms" can also refer to alkenediyl of 2 to 6 carbon atoms which bridges two groups; examples include ethylene-1,2-diyl
(vinylene), 2-met i 1 -2-buten- 1, 4 -dii lo, 2-hexen-l, 6-diyl, etc. "Alkynyl of 2 to 6 carbon atoms" means a straight or branched carbon chain having at least one carbon-carbon triple bond, '. and from two to six carbon atoms; examples include ethmyl, propynyl, butyl, and hexinyl. "Aryl" means aromatic hydrocarbon having from six to ten carbon atoms; examples include phenyl and naphthyl. "Substituted aryl" means aryl independently substituted with one to five (but preferably one to three) groups selected from alkanoyloxy of 1 to 6 carbon atoms, hydroxy, halogen, alkyl of 1 to 6 carbon atoms, trifluoromethyl, alkoxy of 1 to 6 carbon atoms, aryl, alkenyl of 2 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms, nitro, amino, cyano, azido, alkylamino of 1 to 6 carbon atoms, di (alkylamino of 1 to 6 carbon atoms), and amido. "Halogen" means fluorine, chlorine, bromine, and iodine; fluorine being the preferred one. "Heteroaryl" means a five- or six-membered aromatic ring containing at least one and up to four non-carbon atoms selected from oxygen, sulfur and nitrogen. Examples of heterolalk include thienyl, furyl, pyrrolyl, imidazoyl, pyrazyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tpazolyl, thiadiazolyl, oxadiazoyl, tetrazolyl, thiatriazolyl, oxa triazolyl, pyridyl, pipmidyl, pyrazinyl, pi r idazinium, triazinyl, tetrazmyl, and similar rings. The compounds of the present invention have the general formula (I)
Where Ri represents a pentose group (A) or a hexose group (B) of the formulas
Preferred compounds of formula I are those wherein in Ri or Ria all substituents are hydrogen except R2, R3 and R4 are each OH; and R5 is NR9R? 0.
Other preferred compounds of formula I are those wherein in Rx or Ria all substituents are hydrogen except R2, R and R5 are each OH; and R 4 is NR 9 R 10, halogen or N 3 (for example azido). Other preferred compounds of formula I are those wherein in Rx or R? A all substituents are hydrogen except R2 R3 and R4 are each OH; and R5 is halogen. Other preferred compounds of formula I are those wherein in Ri or Ria all substituents are hydrogen except R5, R3 and R4 are each OH; and R2 is halogen. Other preferred compounds of formula I are those wherein in R 1 or R α all substituents are hydrogen, except R 2, R 3 are each OH; and R5 is halogen and R4 is azido or NR9R? 0 or OR. Other preferred compounds of the formula I are those wherein in Ri or R? A all substituents are hydrogen, except R2, R3 are each OH; and R5 is halogen and R4 is halogen or hydrogen or alkyl. Other preferred compounds of formula I are those wherein in Ra or Ria all substituents are hydrogen, except R2, R3 are each hydrogen or hydroxyl; and R is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R 4 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR 9 R 0. Other preferred compounds of formula I are those wherein in Ri or Ria all substituents are hydrogen, except R3 and R4 are each hydrogen or hydroxyl; R 2 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R5 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R? 0. Other compounds of formula I are those wherein in Ri or Ria all substituents are hydrogen, except R3 and R5 are each hydrogen or hydroxyl; R 2 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R4 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R? or - Other preferred compounds of formula I are those wherein in Rx or Rl all substituents are hydrogen, except R2 and R4 are each one hydrogen or hydroxyl; R3 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R5 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R10.
Other preferred compounds of the formula I are those wherein R7 and e taken together is oxygen. Other preferred compounds of formula I are those wherein Xi, X'i. X2 and X'2 are independently halogen (preferably fluoro). The pharmaceutically acceptable salts and / or solvates of the compounds of the formula I also comprise the present invention, which also includes the stereoisomers such as enantiomers which may arise as a consequence of the structural asymmetry in the selected compounds of the formula I, and the anomers that arise from the stereochemistry of the Ri substitution. The compounds of this invention may exist in the form of pharmaceutically acceptable salts. Such salts include the addition salts with the inorganic acids such as, for example, hydrochloric acid and sulfuric acid, and with organic acids such as, for example, acetic acid, citric acid, methanesulfonic acid, toluene sulfonic acid, tartaric acid, and acid maleic In addition, in the case of the compounds of this invention which contain an acid group, the acid group may exist in the form of alkali metal salts such as, for example, a potassium salt and a sm salt; the alkaline earth metal salts such as, for example, a magnesium salt and a calcium salt; and salts with organic bases such as an ethylammonium salt and an arginine salt. The compounds of the present invention are useful pharmacological agents with antitumor properties. With the active properties of topoisomerase I, the compounds may also be useful as antitumor agents. In recent years, numerous reports have been added to the literature suggesting the role of drugs that target topoisomerase I, to stabilize a covalent complex of DNA-topoisomerase I to produce the breaks of a single strand of DNA, linked to enzyme . From a pharmacological point of view, there are advantages in targeting topoisomerase I; Firstly, the relatively high levels of its presence in proliferating and resting cells suggest that its function may be independent of the rate or rate of cell growth and secondly, the active agents of topoisomerase I may be effective in slow development as well as in the rapid proliferation of tumors. Cells in colon tumors have been shown to contain higher intracellular levels of topoisomerase I than normal mucosal cells, suggesting the possibility for selective cytotoxic advantage. Thus, the inhibition of the proliferation of tumor cells by the compounds of formula I was initially demonstrated by the effective inhibition of topoisomerase I. Selected compounds of formula I, which usually have EC5o values less than 10 μM in the topoisomerase I assay, they were also tested in an inhibition of the proliferation assay of human / mouse tumor cells. The compounds of this invention were also examined for their therapeutic effect against the mouse tumor (P388) and the results are shown in the following examples of pharmacological tests (Table 1).
Anti-tumor efficacy Jn Vi vo
The anti-tumor experiments were initiated by implanting mice (BDF1 or CDF1) intraperitoneally with 10 (6) P388 leukemia cells. The treatments were initiated one day after the implant and involved an intraperitoneal injection by dose level; Several dose levels were evaluated per compound. Six mice were typically used per dose level in the treatment groups, and eight to ten mice were used as untreated, parallel leukemic controls. The evaluation of the activity was carried out based on the comparison of the mean survival time (MST) of the treated mice (T) with the MST of the control mice (C). The activity was defined as a% T / C > o = 125%, calculated as: MST (T) / MST (C) x 100 =% T / C
Table 1 Dose Elaborated Compound Using the Example Tumor (mg / kg / dose) MST T / C (%)
No. 19 P388 200 9.0 82 100 20.0 182 50 18.5 168 25 17.0 155
29 P388 200 10 91 100 16.5 150 50 12.0 109 25 14.0 127 Topoisomerase I Activity (In Vi tro)
The activity of topoisomerase I was measured as described below: the procedure for evaluating the compound induced the formation of the single strand break, mediated by topoisomerase I, in the DNA, was essentially as described by Hsiang et al. which appears in J. Biol. Chem. 260: 14873-14878 (1985). The samples dissolved in 100% DMSO either as 10 μM or 10 mg / ml solutions, unless otherwise stated, were diluted in Tris-EDTA buffer. The marine bacteriophage PM2 DNA (Boehringer Mannheim) was also diluted in Tris-EDTA buffer at a concentration of 0.02 μg / μl. Different dilutions of the compound that was evaluated were mixed with the diluted DNA and this mixture was added to 1000 units (one unit of enzymatic activity is defined as the amount capable of relaxing 100 ng of supercoiled DNA in approximately 30 minutes at 37 ° C) of aliquots of purified human topoisomerase I (Topogen) in 2X reaction buffer to start the reaction. The compound-DNA-enzyme mixture was incubated for 30 minutes at 37 ° C before stopping the reaction with warm stop buffer containing sodium dodecyl sulfate and proteinase K (Sigma). These mixtures were allowed to incubate at 37 ° C for another 10 minutes, at which time the mixtures were removed from the water bath and extracted with a 24: 1 mixture of chloroform / isoamyl alcohol. After centrifugation, the aliquots of the aqueous phases were placed in 0.9% agarose gel (SeaKem) wells in Tris-borate buffer containing 0.5 μg / ml ethidium bromide, and subjected to electrophoresis for 15 hours to separate the different topological isomers and the cleaved and broken DNAs. After destaining the gel in water, the reaction products of the DNA stained with ethidium bromide were visualized by exposure of the gel to the ultraviolet irradiation. The negatives of the photographs of the irradiated gels were explored with a densitometer and the areas under the peaks were calculated, in order to obtain the percentage formation of the breakage of the single-strand DNA for each sample. An average effective concentration (EC50) was obtained for each compound by interpolation between the points of the resulting dose-effect curve, which defines the potency of the compound for its effect for the induction of single strand breaks mediated by topoisomerase I in the DNA The topoisomerase I activity for the selected compounds of the present invention is shown below in Table II.
Table II Example No. EC50 (μM) 15 0.03 18 > 100 19 0.04 29 0.01 30 < 0.01 31 < 0.01 33 0.23 34 0.23 35 0.75 45 0.28 47 0.10 48 0.40 68 0.03 69 0.03
The novel compounds of the present invention, as exemplified by the amino derivatives and other sugar derivatives in Table II, show the remarkable activity of topoisomerase I even in the sub-chromosomal concentration range. A priori, this activity, however, is unexpected and unpredictable by someone with experience in the technique, since a small change in substitution patterns seems to result in a highly unexpected change in activity. This is exemplified by the difference in the activity of topoisomerase I for the compounds prepared by Examples 18 and 19. Example 19 is an effective antitumor agent with sub-micromolar Topo-I activity while Example 18 did not show the activity of Topo-I even more than the concentration of 100 micromolar. The only difference between the compounds of Examples 18 and 19 is that in Example 18 Xa and XX is 2,10-difluoro and R 6 is amino, while in Example 19 Xi and X'i is 3,9-difluoro and R6 is hydrogen. In addition, rebeccamycin, where Xi and X'i is 1,11-dichloro, R is methoxy and R 5 is hydroxyl, is also not Topo-I active.
Cytotoxicity activity based on Cells, In Vi tro
The activity of inhibiting proliferation against the human colon cell line was measured as follows. Cytotoxicity was evaluated in HCT116 human colon carcinoma cells by XTT (2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl) -5 - [(phenylamino) carbonyl] -2H- hydroxide assay tetrazolium as described in the literature by Scudiero, DA, Shoemaker, RH, Paull, KD, Monks, A, Tierney, S, Nofziger, TH, Currens, MJ, Seniff, D, and Boyd, MR. soluble tetrazolium / formazan for cell growth and drug sensitivity in the culture using human and other tumor cell lines was performed according to the procedure described in Cancer Res. 48: 4827-4833, 1988. The cells were placed in plaque at 4000 cells / well in 96-well microtiter plates and 24 hours later the drugs were added and serially diluted.The cells were incubated at 37 ° C for 72 hours, at which time the tetrazolium dye was added, XTT , containing phenazine methosulfate An enzyme dehydrogenase in living cells reduces the XTT to a form that absorbs light at 450 nm, which can be quantified spectrophotometrically. The greater the absorbance, the greater the number of living cells. The results are expressed as an IC50 which is the concentration of the drug required to inhibit cell proliferation (eg, absorbance at 450 nm) at 50% of that of untreated control cells. The results for the selected compounds of the present invention are shown in Table III.
Table III
Example No IC50 (μM) 15 0.26 18 > 1.45 19 0.11 29 0.09 33 0.17 35 0.50 45 0.37 58 0.07 60 0.17 Table III (continued)
Example No. IC5o (μM; 62 0 ... 5 6 63 0 ... 7 7 67 0 ... 7 4
One aspect of the present invention involves the administration of the compound of formula I or a pharmaceutically acceptable salt and / or solvate thereof, to a mammal implanted with tumor or susceptible to cancer formation. In general, the compound could be administered in a dose range of about 0.01 mg / kg to about the MTD (maximum tolerated dose). Although the dosage and dosing regimen and programming of a compound of formula I must in each case be carefully adjusted, using sound professional judgment and considering the age, weight and condition of the patient, the route of administration and the nature or the degree of condition of the cancer disease. The term "systemic administration" as used herein refers to the oral, sublingual, buccal, transnasal, transdermal, rectal, intramuscular, intravenous, and traventricular, intrathecal, and subcutaneous routes. In accordance with good clinical practice, it is preferred to administer the present compounds at a concentration level which will produce beneficial beneficial effects without causing any harmful or unwanted side effects.
DESCRIPTION OF THE SPECIFIC MODALITIES
The process for the preparation of the compounds of the formula I is illustrated in Scheme I, and the preparation of the key materials is illustrated in Scheme II.
Scheme I
Synthesis of the Products of the formula I
where: y = B r o C 1; R '= H; R "'= H or a monosaccharide derivative; R" = H or aryl or heteroaryl Scheme II
Key Intermediaries
In Schemes I and II, R2 to R6, Xi, X2, Xi, X2- and Q are as defined above. PG is a synthetic organic "protecting group" of the type generally used to "protect" a hydroxyl functional group, for example an acyl group such as an acetyl group, trifluoroacetyl or an arylalkyl group such as the benzyl group or the like. Suitable "protecting" or "blocking" groups used in organic synthesis are well known to the practitioner and are suitably described in the appropriate literature. See, for example, Theodora Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, New York. The starting materials in Scheme I are di-halomaleimide (II) derivatives, such as 3,4-dibromomaleimide; and the substituted indole derivatives of formula III. The addition of the indole derivatives III (R "= H or AR) to the maleimide II in the presence of a base such as ethylmagnesium bromide or the like in organic solvents such as THF (for example tetrahydrofuran), benzene or toluene or combinations of the at -20 ° C up to the reflux temperature, could result in the mono and bis derivatives V and IV respectively The amount of the reagents can be controlled to vary the proportion of the product of V versus IV in favor of one Intermediate IV can be further transformed into the core of indolopyrrolocarbazole VI by the use of oxidative cyclization conditions such as dicyanodichloroquinone (DDQ) / acid / heat or palladium acetate / acid or iodide, light and the like. with reactive sugar derivatives such as 1,2-epoxide described in the publications J. Org. Chem. 1993, 58, 343-349 and J. American Chemical Society 1989, 111, 6661-6666 or 1-halo and others in presence of a Suitable base such as diisopropylethylamine, hexamethyldisilazide, to form the mono- or di- or tri-anion of the indolopyrrolocarbazole nucleus VI in organic solvent such as tetrahydrofuran, DMF (for example dimethylformamide), dioxane, benzene, DME (for example dimethoxyethane) produces fully protected derivative VIII. Alternatively, more preferably, glycosylation can also be carried out by the reaction of the 1-hydroxyl form of a sugar derivative appropriately protected with the core VI under the well-known Mitsunobu process [PPh3 / dialkyl lazidodicarboxylate] in solvent ethereal such as tetrahydrofuran or chlorinated solvent such as methylene chloride. The sugar derivative suitable for glycosylation can be obtained by selective modification of the different hydroxyl groups using the methods of the literature. For example, the article that appears in J. Carbohydrate Chemistry (1995), 14 (9), p 1279-94 describes the 6-halo-6-deoxyglucose derivative. Yet another method to obtain compound VIII involves glycosylation of the mono adduct, first under the conditions described above to give intermediate VII, followed by dehydrohalogenation and cyclization using a number of well known methods published in the art, for a transformation of this type, including heat or irradiation with ultraviolet light to a solution of intermediate VII in solvents such as dioxane, ethanol or an appropriate mixture of solvents. Compound VIII is a protected form of Formula I. The judicious choice of the protecting group in the sugar would allow selective manipulation of the primary hydroxyl group. For example, when the 6'-primary hydroxyl group was protected with the p-methoxybenzyl protecting group (PMB) and the rest of the hydroxyls were protected with simple benzyl groups (Bn), it is possible for one skilled in the art to eliminate the PMB group without deprotecting the benzyl group. In this way, the primary 6-hydroxyl group is oxidized to the corresponding acid, and its ester and amide derivatives. Further, under conditions of controlled oxidation using the Dess-Martin reagent or the like, the 6-hydroxyl group is oxidized to the corresponding aldehyde. The treatment of the aldehyde with the fluorination reagent well known as DAST, resulted in the 6-difluoromethyl derivative. Similarly, other hydroxyl groups were also modified. For example, when the 4-hydroxyl group of the sugar-galactose derivative (hexose sugar in the form of pyranose in which the 4-hydroxyl group is oriented in the axial position) can be used to modify the 4-position. Oxidation of group 4 -hydroxyl of the appropriately protected sugar derivative, provided the ketone which could be further functionalized to different derivatives including the 4-difluoro derivative using the known procedures. If the 4-hydroxyl group is activated, for example in the case of 4-mesylate, this is susceptible to nucleophilic displacement by agents such as an azide (for example sodium azide) to provide the 4-azido derivative. On the other hand, when the sugar derivative with the unprotected 4-hydroxyl group is treated with the fluorinating agent, DAST, the 4-fluoro derivative is obtained. Similarly, other hydroxyl groups are also selectively modified. For example, the modification of the procedure published in the literature allows the introduction of a fluorine atom in position 2 of sugar (Bioorg, Med.
Chem., Vol. 5, No. 3, pp. 497-500 (1997). This is illustrated in Example 90. The manipulation of the simple protective group such as hydrogenation or transfer hydrogenation with the Pearlman catalyst to remove the benzyl protecting groups from the sugar moiety, or if necessary, the hydrolysis with potassium hydroxide or sodium hydroxide of the nitrogen-protecting group of the maleimide to give the anhydride after an acid treatment followed by heating with an appropriate amine, could produce the desired compound of the formula la with the correct substitution pattern. Selective derivatization of each hydroxyl group in the sugar portion of the compound can be achieved by the use of the protective group manipulation and removal of the primary hydroxyl protecting group, in the presence of the secondary naphthyl protecting groups. For example, when the compound of the formula la, in a glucopyranosyl form (for example the hexose formula
(B)), wherein all hydroxyl groups of the sugar are free, treated with a silyl reagent such as trimethylsilyl or t-butyl-d-phenylsilyl or preferably t-butyl-di-methylsilyl triflate in the presence of a base in a solvent such as methylene chloride or tetrahydrofuran at cold or ambient temperature, derivatives are obtained wherein positions 3 and 6 are protected as silyl ethers. Selective deprotection of the silyl ether in the 6-position can be achieved under controlled conditions of inorganic or aqueous organic acid such as trifluoroacetic acid, and an aqueous mixture as a solvent at a cold temperature such as -25 ° C to 0 ° C in a 30 minute period up to 3 hours, or until the reaction is complete as is followed by thin layer chromatography. This intermediate is now ready for further derivatization at position 6, to activate the 6-hydroxyl to a good leaving group as mesylate or halide. Thus, methanesulfonyl or toluenesulfonyl chloride or trifluoromethanesulfonyl in the presence of a base such as triethylamine or pyridine could produce the corresponding mesylate or tosylate. Alternatively, selective mesylation of the primary 6-hydroxyl group can be carried out directly from the compound of the formula la wherein all the hydroxyl groups of the sugar are deprotected, under pyridine and mesyl chloride in pyridine at 0 ° C. Nucleophilic displacement with an appropriate amine or other nucleophiles such as azide, followed by reduction of the azide to amine could then produce the desired compounds of the formula I such as the 6'-aminocarbon derivatives Ib. In this manner, the 6-methyl sulfide derivative was prepared using either the sodium salt of the thiol derivative or the thiol, and a base such as potassium carbonate in dimethylformamide or an organic amine base such as triethylamine or the base of Hunig at varying temperatures from room temperature to 150 ° C. The 6-alkyl sulfide, for example 6-methyl sulfide, is further oxidized by oxidation agents known as Oxone or m-chloroperbenzoic acid or, preferably, the magnesium salt of monoperoxyphthalic acid (MMPP) to its sulfoxides and sulfone under controlled conditions. Similarly, other hydroxyl groups may be derivatized as desired. A further modification of formula I could result in the indolopyrrolocarbazole derivatives substituted with N-maleimide (for example R6) For example, the anhydride obtained from the basic hydrolysis of the appropriately protected form of formula I is it could be reactivated with a number of amine derivatives to produce the desired N-substituted maleimides As described in Scheme II, the N-substituted maleimide derivative can be obtained either directly from the dihalomaleic anhydride after treatment with a appropriate amine derivative or halogenation of the maleimide, followed by alkylation. The initial indole derivatives, which do not have substitution in the 2-position can be obtained following the published procedures, and the 2-arylindoles can be prepared from the aryl-methyl-ketones following the synthetic procedures of Fisol's Indole, either known. The compounds constituting this invention and their methods of preparation will appear more fully from a consideration of the following examples, which will be for purposes of illustration only and are not intended to be limiting of the invention in scope or in scope. The various intermediate compounds as well as other conventional starting materials, for example, II, III and IX; used in the preparation of final products I, were generally commercially available. The representative synthesis of some of the final compounds of the formula I (wherein in Ri all substituents are hydrogen unless otherwise mentioned) are given hereinafter. The syntheses of some of the intermediates are also provided as in Examples 1-11, 14, 91-96, 98-102, 104 and 105. All anhydrous reactions were carried out under a nitrogen or argon atmosphere using anhydrous solvents , from Aldrich bottles of hermetic sealing or freshly distilled solvents. Column chromatography was performed with silica gel 60 (E M Science, 230-400 mesh) using the aforementioned solvent system as eluent. Thin layer chromatography was conducted on silica gel plates Anatech GFLH or Whatman MK6F. The melting points were determined in an open capillary tube with a Thomas-Hoover melting point apparatus, unless otherwise stated and not corrected. The infrared spectra were recorded in a Perkin-Elmer 1800 Fourier transformation spectrophotometer, such as thin films or potassium bromide pellets. The proton nuclear magnetic resonance spectra (1H NMR) and the carbon 13 nuclear magnetic resonance spectra (13C NMR) were recorded on either Bruker AM-300 or JEOL 300 or Bruker AC-300 nuclear magnetic resonance instruments or 500 MHz, and are expressed as parts per million (ppm od) from the solvent mentioned as the internal standard. The coupling constants are in hertz and the signals are cited as singlet (s), triplet (t), quartet (q), multiplet (m), and broad (br). The low resolution mass spectra were determined on either a Finnigan Model 4500 quadrapolar mass spectrometer by direct chemical ionization (DCI) with isobutane as the positive Cl gas, a Finnigan Model SSQ-7000 instrument (negative or positive ESI) or a Kratos MS-25 or Finnigan TSQ-70 (FAB) instrument. High resolution mass spectra (HRMS) were determined on either a Kratos MS-50 mass spectrometer using rapid bombardment of atoms with cesium iodide in glycerol as the reference agent or on a Finnigan MAT-900 instrument using ionization Electro-debris with polypropylene glycol as the reference agent.
Example 1
3, 4-dibromomaleimide (II; R6 = H, y = Br).
To a magnetically stirred solution of maleimide (25.0 g, 0.258 mol) in deionized water
(250 ml) Bromine (100 g, 0.626 mol) was added rapidly followed by benzoyl peroxide (300 mg). The reaction mixture was heated at 50 ° C for 6.5 hours, and then stirred at room temperature for 11.5 hours. The reaction mixture was cooled in an ice / water bath for 45 minutes, and the solid precipitate was filtered, washed with water, and dried with air to give 36.35 g (55.4%) of the title compound as a white solid. 13 C NMR at 75 MHz (d6-acetone): d 165.08, 130.73; mass spectrum of fast atom bombardment (FAB), m / e 253 (M +); Analysis Calculated for C4HBr2N02: C, 38.30; H, 2.05; N, 4.06; Br 46.32. Found: C, 38.28; H, 2.06; N, 4.07; Br, 46.24.
Example 2
1- (tert-butylbenzyl) -3,4-dibromomaleimide (II; e = tert-butylbenzyl, y = Br)
To a magnetically stirred solution of 3,4-dibromomaleimide (20.0 g, 78.5 mmol) in acetone (1200 mL) was added potassium carbonate (132 g, 0.954 mol). Then 4- (t-butyl) benzyl bromide (24.98 g, 20.2 ml, 110 mmol) was slowly added in 15 minutes and the reaction mixture was stirred for 6 hours in the dark. The reaction mixture was filtered on a pad of Celite and washed with acetone (250 ml). Evaporation in vacuo, followed by flash chromatography on silica gel with 50% hexane in dichloromethane, gave 22.5 g (71.5%) of the title compound as a white solid. 1 H NMR at 300 MHz (CDC13) d 7.45-7.25 (m 4 H), 4.75 (s, 2 H), 1.32 (s, 9 H); DCI mass spectrum, m / e 399 (M +); Analysis Calculated for C? 5H15Br2N02: C, 44.92; H, 3.77; N, 3.49. Found: C, 45.04; H, 3.81; N, 3.38.
Example 3
2- (2-benzo [b] thienyl) -5-fluoro-lH-indole (III: Xi = 5F; X2 = H; R "= 2-benzo [b] thienyl, R '= H)
N-Butyllithium in hexanes (1.6 M, 255 mL, 0.41 mmol) was added in 5 mL portions to a cold (4 ° C) solution of tianaphthene (47.8 g, 0.36 mol) in anhydrous tetrahydrofuran / diethyl ether (1 : 1, 400 ml) under a nitrogen atmosphere. The lithium alkyl was added at such a rate that the internal reaction temperature never exceeded 8 ° C. After the addition was complete, the reaction mixture was allowed to warm to room temperature, where it was stirred for 1 hour before it was cooled again to 4 ° C and carefully treated with an acetaldehyde solution (50 ml) in anhydrous tetrahydrofuran (50 ml). The mixture was allowed to warm to room temperature for 0.5 hours before it was quenched with water and diluted with ethyl acetate. The organic phase was separated, washed with brine, dried and concentrated. The aqueous phase was extracted twice more with ethyl acetate and combined with the original organic extract before further work. Purification of the resulting residue by flash chromatography on silica gel (gradient elution with 7% ethyl acetate in hexanes, followed by 15% ethyl acetate in hexanes) provided 29.25 g (46%) of the intermediate alcohol as a solid pale yellow which was then treated directly. The alcohol (29.15 g, 0.16 mol) was dissolved in anhydrous dichloromethane (800 ml) and the reaction mixture was treated with Celite (36 g) and pyridinium chlorochromate (35 g). After one hour at room temperature, additional dichloromethane (400 ml), Celite (36 g) and PCC were added.
(35 g). The mixture was further stirred for an additional 1 hour at room temperature, before it was diluted with ether (1 L), filtered through suction through a pad of silica gel and concentrated.
Methyl ketone (27.6 g, 96%) was isolated as a white, pure solid. Anhydrous sodium acetate was added
(16.6 g, 0.20 mole) in one portion to a stirred suspension of 4-fluorophenyrazine hydrochloride (32.98 g, 0.20 mole) and methyl ketone (27.5 g, 0.156 mole) in absolute ethanol (150 ml). The mixture was heated to reflux for 2 hours before it was cooled, to be diluted with dichloromethane and washed with saturated sodium hydrogen carbonate solution, IN hydrochloric acid and brine. After drying and evaporation of the solvent, the residue was recrystallized from hot ethanol to give the pure hydrazone (40.08 g, 90%) as a yellow solid. The hydrazone (18.3 g, 64.4 mmol) was placed in a 500 ml single-neck round bottom flask (equipped with a reflux condenser) which contained freshly fused zinc chloride, under a nitrogen atmosphere. The flask was then placed in a preheated oil bath (180 ° C) for 1 hour. After 1 hour, the temperature of the oil bath was allowed to cool to 140 ° C before the flask was carefully charged with absolute ethanol. The mixture was heated to reflux for 6 hours before it was cooled, diluted with ethyl acetate and washed with IN hydrochloric acid and brine, before drying and concentration of the solvent to 1/3 of the volume. Suction filtration gave the title compound (22.4 g, 65%) as a white solid, m.p. 263-264 ° C; XR NMR (300 MHz, DMSO-dβ) d 11.91 (s, ÍH), 7.99-7.96 (, ÍH), 7.89-7.86 (m, 2H), 7.83 (s, ÍH), 7.43-7.29 (series of m, 4H), 7.03-6.96 (m, HH), 6.81 (d, J = 1.5 Hz, HH), 13C NMR (75 MHz, DMSO-d6) ppm 158.79, 155.72, 140.01, 138.35, 134.92, 133.92, 133.79, 128.64 , 128.50, 124.93, 124.79, 123.70, 122.44, 119.73, 112.35, 112.22, 110.76, 110.41, 104.90 104.59, 100.90, 100.84; IR (KBr, cm "1) 3421, 1625, 1586, 1567, 1501, 1448, 1412, 1286, 1201, 1188, 1128, 862, 825, 783, 744, 725, 559, 515 ms (NEG. Esi, MH ") m / z 266. Analysis Calculated for d6H10FNS: C, 71.89; H, 3.77; N, 5.24. Found: C, 71.82; H, 3.76; N, 5.13.
Example 4
(E) -4-fluoro-2-nitro-β-dimethylaminoes tireno
A mixture of 4-fluoro-2-nor trotoluene (185.0
1. 19 mol) dimethylacetal of the N, N-dimethylformamide (500 ml, 3.77 mol) in anhydrous dimethylformamide was heated at reflux for 2 hours under nitrogen atmosphere before the azeotropic distillation of methanol from the reaction mixture. Another tandem reaction was performed (169.2 g of 2-fluoro-2-trotoluene). A combined weight of 450 g (95%) of the title compound was isolated as a red solid (solidified upon cooling) which was pure enough to be used subsequently. Distillation from Kugeirohr provided the title compound (analytically pure for characterization purposes) as a reddish black crystalline solid, m.p. 54-55 ° C; NMR XH (300 MHz, DMS0-d6) d 7.72-7.62 (m, 2H), 7.37-7.32 (m, 1H), 7.33 (d, J = 13.4 Hz, ÍH), 5.58 (d, J = 13.4 Hz, ÍH), 2.58 (s, 6H); 13 C NMR (75 MHz, DMSO-d 6) ppm 158.19, 154.99, 146.16, 143.13, 143.02, 132.57, 132.54, 126.14, 126.04, 120.98, 120.69, 111.41, 111.07, 88.23; IR (KBr, cm "1) 3446, 1622, 1570, 1508, 1386, 1270, 1092, 940, 822, 798; MS (MH +) m / z 211. Analysis Calculated for C 10 HnFN 2 O 2: C, 57.14; H, 5.27; N, 13.33, Found: C, 57.09; H, 5.16; N, 13.46.
Example 5
6-fluoroindole (III: Xa = F, X2 = R "= R '= H)
The (E) -4-fluoro-2-nitro-β-dimethylaminostyrene (120 g, 0.5 mol) was dissolved in tetrahydrofuran (1 L) and subjected to Parr hydrogenation (3.51 kg / cm2 (50 psi) of H2 , at room temperature, 24 hours) using 10% palladium on carbon (30 g). The mixture was filtered through Celite (washed with tetrahydrofuran, methanol and methylene chloride) and concentrated to dryness. This reaction was performed three additional times in order to consume the initial material mentioned above. Steam distillation of the residue afforded the title compound (192.6 g, 62%) as white needles, m.p. 73-75 ° C; NMR XH (300 MHz, DMSO-ds) d 11.14 (broad s, HI), 7.51 (dd, J = 8.6,
. 5 Hz, ÍH), 7.32 (t, J = 2.9 Hz, ÍH), 7.16 (dd, J =
. 1, 2.3 Hz, ÍH), 6.87-6.80 (m, ÍH), 6.43-6.41 (m,
ÍH); 13 C NMR (75 MHz, DMSO-d 6) ppm 160.26, 157.16,
135. 79, 135.63, 125.94, 125.89, 124.42, 120.97, 120.83, 107.43, 107.10, 101.17, 97.47, 97.13; GO
(KBr, c "1) 3392, 3072, 1626, 1508, 1448, 1342, 114,
954, 846, 802, 728, 508; MS (MH +) m / z 136. Analysis
Calculated for C8H6FN: C, 71.10; H, 4.47; N, 10.36.
Found: C, 71.28; H, 4.69; N, 10.24.
Example 6
3, 4-bis (5-fluoro-l-indol-3-yl) -N- [4- (t-butyl) -benzyl] -pyrrole-2, 5-dione (IV: Xx = F; X2 = R 'or R "= H; R6 = 4- (t-butyl) benzyl)
To a magnetically stirred solution of 5-fluoroindole (7.0 g, 51.8 mmol) in anhydrous benzene
(125 ml) was added under an argon atmosphere with stirring, methyl magnesium iodide (3.0 M in ether;
18. 0 ml, 54.0 mmol). The mixture was stirred at room temperature for 30 minutes and then this solution was added via a cannula in a period of 10 minutes, to a rapidly stirred solution of N- [4- (t-butyl) benzyl] -3.4 -dibromomaleimide (6.50 g, 16.2 mmol) in anhydrous benzene (60 ml). The resulting dark purple solution was stirred at room temperature under an argon atmosphere for 16 hours, and was poured into a mixture of 20% aqueous citric acid (350 ml) and ethyl acetate (500 ml). The organic layer was washed with water (200 ml) and brine (200 ml), and dried (sodium sulfate). Evaporation in vacuo followed by flash chromatography on silica gel with 100% dichloromethane, followed by 10% ethyl acetate in dichloromethane, gave 3.68 g (44%) of the title compound as a red solid. XH NMR at 300 MHz (CDC13) d 8.63 (broad s, 2H), 7.87 (d, 2H, J = 2.9 Hz), 7.46-7.34 (m, 4H), 7.23 (dd, 2H, J = 8.9, 4.4 Hz ), 6.79 (ddd, 2H, J = 9.1, 8.9, 2.5 Hz), 6.48 (dd, 2H, J = 10.2, 2.5 Hz), 4.83 (s, 2H), 1.30 (s, 9H); 75 MHz 13 C NMR (CDC13) d 172.15 (s), 157.73 (d, J = 235 Hz), 150.82 (s), 133.79 (s), 132.27 (s), 129.92 (s), 128.32 (s), 127.14 (s) s), 126.16 (d, J = 10.4 Hz), 125.72 (s), 112.19 (d, J = 9.8 Hz), 111.10 (d, J = 26.6 Hz), 106.95 (d, J = 4.3 Hz), 106.43 ( d, J = 25.1 Hz), 41.68 (s), 34.55 (s), 31.33 (s); mass spectrum FAB, m / e 509 (M +).
Example 7
3-bromo-4- (6-fluoro-lH-indol-3-yl) - lH-pyrrole-2, 5-dione (V: Xi = 6F; R '= R "= R6 = H; y = Br) and 3,4-bis (6-fluoro-1H-indo-3-yl) -lH-pyrrole-2, 5-dione (IV: Xa = F; X2 = R '= R "= R6 = H)
To a solution of 6-fluoroindole (50.0 g, 0.37 mol) in anhydrous benzene (1 L) under nitrogen atmosphere was added by means of a syringe, ethylmagnesium bromide (3M, 130 ml, 0.43 mol) at a rate that maintained the internal temperature between 45-50 ° C. The mixture was then heated to 50-55 ° C for 0.5 hours before a suspension of 2,3-dibromomaleimide (24.9 g, 0.093 mol) in anhydrous benzene was drained into the reaction mixture. The mixture was refluxed for 22 hours, cooled, diluted with ethyl acetate, and acidified to pH = 1 with IN HCl. The organic phase was then separated, washed with brine, dried and concentrated. The aqueous phase was diluted once more with ethyl acetate and separated. The resulting organic phase was treated in an identical manner as mentioned above and combined with the original. Another 50 g reaction was performed and combined before chromatography. Purification of the combined residues by flash chromatography on silica gel (gradient elution with 10% acetate in hexanes followed by 20% and finally 40% ethyl acetate in hexane) provided two main products. The title compound of formula V was isolated (12.31 g, 21.5% as a brick red solid and the title compound of formula IV (31.5 g, 41%) as a reddish-orange foam. title of formula V: mp 73-75 ° C; XH NMR a (300 MHz, DMSO-d6) d 11.14
(s broad, ÍH), 7.51 (dd, J = 8.6-5.5 Hz, ÍH), 7.32
(t, J = 2.9 Hz, ÍH), 7.16 (dd, J = 10.1, 2.3 Hz, ÍH),
6. 87-6.80 (m, ÍH), 6.43-6.41 (m, ÍH); 13 C NMR (75
MHz, DMSO-de) PPm 160.26, 157.16, 135.79, 135.63, 125.94, 125.89, 124.42, 120.97, 120.83, 107.43, 107.10, 101.17, 97.47, 97.13; IR (KBr, cm "1) 3392, 3072, 1626, 1508, 1448, 1342, 1144, 954, 846, 802, 728, 508; MS (MH +) m / z 136. Analysis Calculated for C8H6FN: C, 71.10; H, 4.47; N, 10.36, Found: C, 71.28; H, 4.69; N, 10.24.
For the title compound of formula IV: p.f. 207-208 ° C (decomposes); X H NMR (300 MHz, DMSO-d 6) d 12.10 (s, ÍH), 11.37 (s, ÍH), 8.03 (d, J = 2.9 Hz, 1H), 7.86 (dd, J = 8.9, 5.4, 2.3 Hz, ÍH), 7.28 (dd, J = 9.6, 2.3 Hz, 1H), 7.00 (dt, J = 9.3, 2.3 Hz, ÍH); 13 C NMR (75 MHz, DMSO-d 6) ppm 170.12, 167.35, 160.70, 157.56, 137.65, 136.62, 136.45, 131.58, 131.56, 123.51, 123.38, 121.27, 115.40, 109.03, 108.70, 103.89, 98.47, 98.14; IR (KBr, cm "1) 3328, 3222, 1726, 1604, 1450, 1338, 1240/1192, 1148, 840, 794; MS (MH +) m / z 309, 311. Analysis Calculated for C? 2H6NrFN202: C, 46.63; H, 1.96; N, 9.06, Found: C, 46.70; H, 2.00; N, 8.94.
Example 8
3, 9-difluoro-12, 13-dihydro-5H-indole [2,3-a] pyrrolo [3,4-c] carbazole-5, 7 (6-N- [4- (t-butyl) encyl] ) -dione (VI: Xi = Xx. = F; X2 = X2 '= R' = H; R6 = 4- (t-butyl) benzyl; Q = NH).
To a magnetically stirred solution of the product of Example 6 (11.6 g, 22.8 mmol) in anhydrous benzene (1700 ml) was added under stirring argon, p-toluenesulfonic acid monohydrate (170 mg) and DDQ (10.9 g, 48.0) mmol). The mixture was heated to reflux under an argon atmosphere with stirring for 1 hour, and stirred at room temperature for 16 hours. The resulting dark precipitate was collected by filtration, washed with cold ethyl acetate (50-70 ml), and dried for 1-2 hours under vacuum to give 12.80 g (94%) of the title compound as a yellow brown solid. (monoethyl acetate complex by proton NMR, further vacuum drying can reduce the ethyl acetate content by a two-thirds means). Recrystallization from tetrahydrofuran / ethyl acetate gives the analytically pure product as a bright yellow solid (monoethyl acetate complex by proton NMR). XH NMR at 300 MHz (d6-DMSO) d 11.83 (broad s, 2H), 8.46 (dd, 2H, J = 9.7, 2.6 Hz), 7.69 (dd, 2H, J = 8.9, 4.6 Hz), 7.36 (ddd) , 2H, J = 9.1, 8.9, 2.6 Hz), 7.34-7.22 (, 4H), 4.63 (s, 2H), 1.22 (s, 9H); mass spectrum FAB, m / e 507 (M +); Analysis Calculated for C3? H23F2N302 • C4H802: C, 70.58; H, 5.25; F, 6.38; N, 7.06. Found C, 70.52; H, 5.31; F, 6.14; N, 7.00.
Example 9
2,10-difluoro-12, 13-dihydro-5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazol-5, 7 (6H) -dione (VI: Xi = Xi- = F; X2 = X2 '= R' = R6 = H; Q = NH)
The 2,3-dichloro-5,6-dicyan-1,4-benzoquinone (15.81 g, 0.70 mol) was added in one portion to a stirred suspension of 3, -bis (6-fluoro-1H-indol-3). il) -lH-pyrrole-2, 5-dione (11.5 g, 0.032 mol) and toluenesulfonic acid monohydrate (0.44 g) in benzene (1 L) under nitrogen atmosphere and the mixture was heated to reflux for 2 hours before it was cooled, stored at room temperature for 16 hours, and filtered by suction through a sintered glass funnel. The precipitate was washed successfully with benzene, with ethyl acetate and with ether until a colorless filtrate was observed. Another 20.0 g reaction was performed in tandem using proportionally the same amount of reagents used in the first reaction. The title compound (15.51 g, 40%) was isolated as a yellowish green solid, m.p. > 305 ° C; NMR XH (300 MHz, DMS0-d6) d 11.67 (broad s, 2H), 10.93 (s broad, ÍH), 8.84 (dd, J = 8.8, 5.8 Hz, 2H), 7.55 (dd, J = 10.0, 2.3 Hz, 2H), 7.11 (dt, J = 9.2, 2.3 Hz, 2H), 4.00 (q, J = 7.1 Hz, 2H), 1.96 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H); 13 C NMR (75 MHz, DMSOde) ppm 171.09, 170.32, 163.27, 160.08, 141.00, 140.83, 129.25, 125.69, 125.55, 119.54, 118.23,
115. 09, 108.51, 108.19, 98.64, 98.28, 59.74, 20.74, 14.07; IR (KBr, cm "1) 3320, 1748, 1690, 1572, 1404, 1376, 1312, 1232, 1144, 1116, 840; MS (M +) m / z 361. Calculated Analysis for C20H9F2N3O2 • 1. OEtOAc • 0.1H20 : C, 63.89; H, 3.84; N, 9.31, Found: C, 64.12; H,
3. 76; N, 9.55.
Example 10
3, 9-di fluoro-12, 13-dihydro-13 - [3, 4, 6-tris-0 (phenylmethyl) -β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6N- [4- (t-butyl) benzyl]) -dione (VIII: Xi = X? - = F; X2 = X2. = R '= R "' = H; R6 = 4 (t-butyl) encyl, Q = NH, PG = benzyl).
To a magnetically stirred suspension of the core of Example 8 (9.50 g, 17.7 mmol) in anhydrous tetrahydrofuran (450 ml) was added sodium bis (trimethylsilyl) amide (5-10 minutes) under argon with stirring. 1.0 M in tetrahydrofuran, 50.0 ml, 2.82 equiv.). The resulting dark red solution was stirred at room temperature for 45 minutes, treated by means of a syringe with chlorotrimethylsilane (5.06 ml, 40.0 mmol), and stirred at room temperature for an additional 1 hour. The reaction mixture was then heated to reflux, and refluxed while adding a solution of 1,2-anhydro-sugar IX (13.5 g, 31.2 mmol, see J. Org. Chem. 1993, 5_8 343-349). ) in anhydrous tetrahydrofuran (200 ml) over a period of 3.5 hours by means of a constant addition funnel. After the addition was complete, the reaction was heated to reflux for 10 hours under an argon atmosphere, treated with a solution of 1,2-anhydro-sugar IX (800 mg) in anhydrous tetrahydrofuran (40 ml) and heated to reflux for 2.5 additional hours. The mixture was cooled to room temperature over a period of 45 minutes, treated with hydrochloric acid (1.0 N, 280 ml), and stirred for 75 minutes. The mixture was partitioned between ethyl acetate (2000 ml) and 0.5 N HCl
(600 ml). The organic layer was washed with saturated aqueous sodium hydrogen carbonate (300 ml), water (350 ml) and brine (400 ml). The original acidic aqueous layer was extracted with fresh ethyl acetate (600 ml) which was then washed with water (100 ml), and brine (150 ml). The combined organic extracts were dried (sodium sulfate) and rotary evaporated to a volume of about 300 ml, after which the resulting yellow precipitate was collected by filtration, washed with ethyl acetate (300 ml), and dried vacuum to give 3.00 g (31.6%) of the recovered pure core. The filtrate was concentrated in vacuo, dissolved in methylene chloride / hexane, and purified by flash chromatography on silica gel using 5-10% ethyl acetate in hexanes. The yellow fractions containing the less polar spot were evaporated to a volume of about 300 ml and allowed to stand overnight to produce 625 mg (3.8%) of beautiful yellow prisms of the N12 product, N? 3-double glycosylated (structure determined by X-ray crystallography). An additional portion of 380 mg (2.3%) thereof was obtained from the mother liquor. Additional elution with 10-15% ethyl acetate in hexanes gave 9.23 g (55.5%, 81% based on the recovered core) of the analytically pure title compound of formula VIII as a yellow solid. XH NMR at 500 MHz (d6-DMS0) d 10.85 (s broad, ÍH), 8.84 (dd, ÍH, J = 9.6, 2.7 Hz), 8.75 (dd, ÍH, J = 9.6, 2.5 Hz), 7.54 (ddd , ÍH, J = 9.1, 9.1, 2.7 Hz), 7.42-7-18 (m, 21H), 6.43 (d, ÍH, J = 8.8 Hz, l'H), 5.38 (d, ÍH, J = 6.3 Hz , 2'OH), 4.94-4.56 (m, 8H), 4.30-4.15 (m, 2H), 3.98-3.72 (m, 4H), 1.24 (s, 9H); mass spectrum FAB, m / e 939 (M +); Analysis Calculated for C58H5iF2N3? 7: C, 74.11; H, 5.47; F, 4.04; N, 4.47. Found C, 73.89; H, 5.51; F, 3.77; N, 4.26.
Example 11
2, 10-di fluoro-12, 13-dihydro-13 - [3, 4, 6-tris-O- (f-enylmethyl-β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3 , 4-c] carbazole-5, 7 (6H) -dione (A = VIII: Xa =
Xi '= F; X2 = X2? = R6 = R "'= H; Q = NH; PG = benzyl) and 2, 10-di fluoro-12, 13-dihydro- 13 - [2-0- [3, 4, 6-tris-O- ( phenylmethyl) -β-D-glucopyranosyl] -3,4,6-tris-O- (phenylmethyl) -β-D-glucopyranosyl 1] - 5H-indolo [2,3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (B = VIII: XI =
XI '= F; X2 = X2 '= R6 = H; Q = NH; PG = benzyl; R "'= 3, 4, 6-tris-0 (phenylmethyl) -β-D-glucopyranosyl).
A solution of sodium bis (trimethylsilyl) amide (IM, 9.1 ml, 3.3 eq.) In tetrahydrofuran was added via syringe to a solution of 2, 10-difluoro-12,13-dihydro-5H-indolo [2]. , 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6H) -dione (11.17 g, 32.38 mmol) in anhydrous tetrahydrofuran (600 mL) at room temperature. After 25 minutes, an epoxide solution (24.27 g, 56.11 mmol, 1.7 eq.) In anhydrous tetrahydrofuran (50 ml) was cannulated into the reaction mixture. The mixture was refluxed for 6 hours before it was quenched with saturated ammonium chloride solution and diluted with ethyl acetate. The organic phase was separated, washed with brine, dried and evaporated. Purification of the residue by flash chromatography on silica gel (gradient elution with 15% tetrahydrofuran in hexanes, followed by 20% and 40% tetrahydrofuran in hexanes) provided the title compound A of formula VIII (6.1 g, %) as a yellow foam, the unreacted aglycone (4.00 g) and the bis-sugar compound B (10.9 g, 34%, MS (M +) calculated for C? 4 HssF2N30? 2 1226.4615, observed 1226.4566) as a yellow foam which was converted directly to the title compound A of formula VIII as described below. For the title compound of the formula A = VIII: p.f. 140-147 ° C; 1 H NMR (300 MHz, CDCl 3) d 10.50 (s, HH), 8.79-8.74 (dd, J = 8.8, 5.8 Hz, ÍH), 8.21 (dd, J = 8.8, 5.6 Hz, ÍH), 7.59-7.33 ( m, 11H), 7.28-7.12 (2m, 11H), 7.06-7.00 (m,
ÍH), 6.81 (dd, J = 9.1, 2.2 Hz, ÍH), 6.61-6.58 (m,
ÍH), 5.83 (d, J = 9.0 Hz, ÍH), 5.12 (d, J = 5.3 Hz,
ÍH), 5.08 (d, J = 5.2 Hz, ÍH), 5.01-4.98 (, ÍH),
4. 85 (d, J = 10.8 Hz, ÍH), 4.73-4.72 (m, HH), 4.55-4.35 (m, 4H), 4.07-3.93 (m, 3H), 3.76-3.72 (m, HH);
3 C NMR (75 MHz, CDCl 3) ppm 169.55, 169.10, 164.43, 164.25, 161.18, 161.00143.00, 142.83, 141.68, 141.50, 137.69, 137.59, 136.32, 130.45, 128.91, 128.74, 128.63, 128.56, 128.43, 128.06, 127.02, 126.89, 126.15, 126.01, 120.00 119.01, 118.44, 118.17, 118.09, 110.33, 110.02, 109.48, 109.16, 98.04, 97.70, 97.34, 85.89, 85.62, 76.35, 75.36, 75.05, 74.09, 73.74, 66.75; IR (KBr, cm "1) '3430, 3334, 2914, 2870, 1752, 1702, 1580, 1452, 1328, 1232, 1140, 1062, 698; MS (M +) calculated for C47H38F2N3? 7 794.2678, observed 794.2687. Calculated for C47H37F2 3.O7-l.OH2O: C, 69.54; H, 4.84; N, 5.17; H20, 2.2 Found: C, 69.57; H, 4.70; N, 5.10; H20, 0.4, Compound B becomes to compound A by stirring a solution of 2, 10-difluoro-12, 13-dihydro-13- [2-0- [3, 4,6-tris-0- (phenylmethyl) -β-D-glucopyranosyl) ] -3,4,6-tris-O- (phenylmethyl) -β-D-glucopyranosyl] -5H-indole [2,3-a] pyrrolo [3,4-c] carbazole-5, 7 (6H ) -dione (10.9 g, 8.89 mmol) in anhydrous ethyl acetate (25 ml) and treatment with a solution of anhydrous methanolic hydrogen chloride (8M, 500 ml) in a sealed flask for 96 hours at room temperature. The solvents were then removed in vacuo and the resulting residue was diluted with ethyl acetate and tetrahydrofuran and neutralized to pH = 8 with saturated sodium hydrogen carbonate solution. The organic phase was separated and washed with brine before drying and the concentration of the solvent. Purification of the residue by flash chromatography on silica gel (as described below) yielded the title compound A of formula VIII (5.7 g, 81%) as a yellow foam, as well as the initial aglycone material (0.7 g). ).
Example 12
3, 9-difluoro-12, 13-dihydro-13- [β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6N- [ 4- (t-butyl) benzyl] -) -dione (la: Xx = X? »= F; X2 = 2- = H; R6 = 4- (t-butyl) benzyl; Q = NH; R2-R5 = OH). To a magnetically stirred solution of the compound of Example 10 (2.10 g, 2.23 mmol) in 95% ethanol (450 ml) and cyclohexane (175 ml) was added 20% palladium hydroxide on carbon (0.49 g) and the mixture was stirred. heated to reflux under nitrogen atmosphere with vigorous stirring for 20 hours. The mixture was filtered hot through Celite and washed with methanol. The filtrate was concentrated in vacuo and purified by flash chromatography on silica gel using 3-5% methanol in methylene chloride to give 1.35 g (90%) of the pure title compound as a yellow-orange solid. The analytical sample was evaporated from ethyl acetate, dried in vacuo, and obtained as 1/2 ethyl acetate complex per molecule. XH NMR at 300 MHz
(d6-DMSO) d 11.81 (s broad, ÍH), 8.84 (dd, ÍH, J == 9.7, 2.7 Hz), 8.76 (dd, ÍH, J = 9.7, 2.6 Hz), 8.04
(dd, ÍH, J = 9.3, 4.4 Hz), 7.70 (dd, ÍH, J = 8.9, 4.6
Hz), 7.55-7.46 (m, 2H), 7.40-7.33 (m, 4H), 6.31 (d,
ÍH, J = 8.9 Hz), 6.12 (s broad, ÍH), 5.43 (d, ÍH, J
= 4.4 Hz), 5.17 (d, ÍH, J = 5.5 Hz), 4.93 (d, ÍH, J = 5.4 Hz), 4.90 (s, 2H), 4.13-4.07 (m, ÍH), 4.00-3.96
(m, 2H), 3.87-3.80 (m, 1H), 3.63-3.46 (m, 2H), 1.24
(s, 9H); mass spectrum FAB, m / e 669 (M +); Analysis
Calculated for • 1/2 C4H802: C, 65.63; H,
. 22; F, 5.32; N, 5.89. Found: C, 65.04; H, 5.20; F, 5.32; N, 5.91.
Example 13
2, 10-difluoro-12, 13-dihydro-13- [β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (the: Xi = Xi '= F; X2 = X2- = R6 = H; Q = NH; R2-R5 = OH).
A solution of 2, 10-difluoro-12, 13-dihydro-13- [3, 4, 6-tris-0- (phenylmethyl) -β-D-glucopyranosyl] -5H-indolo [2,3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (4.36 g, 5.49 mmol)) in a mixture of ethanol and ethyl acetate (1: 1, 100 ml) was subjected to hydrogenation of Parr (H2) , 4.22 kg / cm2 (60 psi)) for 6 hours at room temperature with 20% Pd (0H) 2 on carbon (4.4 g) as catalyst. After filtration by suction through Celite, the filtrate was concentrated to dryness to yield an orange-yellow residue which was purified by flash chromatography on silica gel (elution with 50% tetrahydrofuran in hexanes) to provide the title compound. Title
(2.33 g, 77%) as a yellow solid, m.p. 255-260 ° C; NMR XH (300 MHz, DMS0-d6) d 11.77 (s, ÍH),
11. 19 (s, ÍH), 9.14-9.03 (m, 2H), 7.89 (dd, J = 11.0, 2.0 Hz, ÍH), 7.41 (dd, J = 9.8, 2.3 Hz, ÍH), 7.27-7.19 (m, 2H), 6.26 (d, J = 8.9 Hz, 1H), 6.14-6.12 (, 1H), 5.43 (d, J = 4.0 Hz, ÍH), 5.17 (d, J = 5.5 Hz, ÍH), 4.98 (d , J = 5.5 Hz, HH), 4.24-3.94 (m, 3H), 3.83-3.81 (m, HH), 3.59-3.57 (m, HH), 3.50-3.42 (m, HH); 13 C NMR (75 MHz, DMSO-d6) ppm 170.99, 170.91, 163.43, 160.24, 143.12, 141.63, 130.09, 128.74, 126.02, 120.90, 119.35, 118.22, 118.14, 117.74, 116.54, 108.78, 108.57, 98.77, 98.55, 98.20 , 86.64, 78.56, 76.44, 73.06, 67.51, 58.29; IR (KBr, cm "1) 3326, 1744, 1700, 1578, 1452, 1328, 1232, 1114, 1074, 828; MS (M +) m / z 523. Analysis Calculated for C26H? 9F2N3O7» 0.25EtOAc »0.40H2O: C, 58.68, H, 3.98, N, 7.60, H20, 1.30, Found: C, 58.55, H, 4.18, N, 7.38, H20, 1.20.
Example 14
2, 10-di fluoro-12, 13-dihydro-13 - [2-0- (triethylsilyl) -3,4,6-tris-0- (phenylmethyl) -β-D-glucopyranosyl] -6-triethylsilyl-5H -indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5,7-dione (A = VIII: X? = Xj. = F; X2 = X2- = H; R6 = R "'= triethylsilyl, Q = NH, PG = benzyl) and 2,10-difluoro-12, 13-dihydro-13- [2-0- (triethylsilyl) -3,4,6-tris-O- (phenylmethyl) -β -D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (B = VIII: Xx = Xi- = F; X2 = X2. = R6 = H; R "'triethylsilyl; Q = NH; PG = benzyl). Triethylsilyl triflate (9.0 ml, 40.0 mmol, 20 eq.) Was added in one portion to a solution of 2., 10-di-fluoro-12, 13-dihydro-13- [3, 4,6-tris-0- (phenylmethyl) -β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (1.60 g, 2.0 mmol) in anhydrous pyridine (100 ml). The mixture was stirred in a sealed flask at room temperature for 48 hours before absolute ethanol (5 ml) was added. After 10 minutes, the solvent was removed under vacuum at room temperature. The residue was then diluted with ethyl acetate and tetrahydrofuran, and acidified with 0.1N hydrochloric acid until acidic. After separation of the organic phase, the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The attempted purification of the residue by flash chromatography (2 times) on silica gel (elution with 10% tetrahydrofuran in hexanes for the first time and 40% ether in hexanes the second time) yielded the title compound A (1.4 g) like a slightly impure yellow foam. The impurity proved to be B. The complete conversion from A to B could be achieved by dissolving A (1.4 g, 1.37 mmol) in absolute ethanol (20 ml) and treating the solution with ammonium acetate (0.11 g, 1.40 mmol ) at room temperature for 2 hours. The mixture was then diluted with ethyl acetate and washed successively with saturated sodium hydrogen carbonate solution and brine before drying and concentration to dryness. The title compound B (1.19 g, 96%) was isolated as a yellow foam. For A: p.f. 77.79 ° C; NMR XH (300 MHz, CDC13) d 10.64 (s, ÍH), 9.29 (dd, J = 8.8, 5.8 Hz, ÍH), 9.23-9.20 (m, ÍH), 7.33-7.20 (m, 15H), 7.13- 7.04 (, 4H), 5.77 (d, J = 8.8 Hz, ÍH), 5.05 (d, J = 11.6 Hz, ÍH), 4.89-4.79 (m, 2H), 4.67-4.63 (m, 2H), 4.54 ( d, J = 12.4 Hz, HH), 4.28 (m, HH), 4.16 (m, HH), 3.97 (m, 2H), 3.79-3.76 (m, 2H), 1.23-1.16 (m, 6H), 1.11 -1.06 (m, 9H), 0.24 (t, J = 8.0 Hz, 9H), -0.29- (-0.50) (m, 6H); 13 C NMR (75 MHz, CDC13) ppm 175.34, 142.70, 141.88, 138.08, 137.40, 136.28, 128.72, 128.56, 128.27, 128.13, 128.05, 127.52, 127.40, 127.17, 126.73, 121.40, 118.12, 109.84, 109.84, 109.53, 109.21 , 98.26, 97.52, 86.12, 77.71, 77.44, 77.01, 76.72, 76.59, 75.53, 75.25, 74.26, 66.82, 6.91, 6.12, 4.03, 3.95; IR (KBr, c "1) 3458, 3334, 2954, 2876, 1692, 1454, 1328, 1300, 116, 1072, 732, 696; MS (M +) calculated for C59H66F2 307Si2 1022.4407, observed 1022.4377 For B: pf not determined; 1 H-NMR (300 MHz, CDC13) d 10.65 (s, HH), 9.25-9.22 (m, HH), 9.14 (d, J = 8.8, 5.6 Hz, HH), 7.72 (s, HH), 7.33- 7.21
(m, 14. H, 7.16-7.03 (m, 4H), 5.77 (d, J = 8.8 Hz, ÍH), 5.05 (d, 'j = 11.5 Hz, ÍH), 4.87-4.78 (m, 2H), 4.69-4.63 (m, 2H), 4.59-4.51 (m, ÍH), 4.28 (t, J = 8.8 Hz, ÍH), 4.15 (t, J = 8.8 Hz, ÍH), 4.02-3.91 (, 2H), 3.79-3.73 (m, 2H), 0.23 (t, J = 8.0 Hz, 9H),
-0.28- (-0.52) (m, 6H); 13 C NMR (75 MHz, CDC13 ppm 169.70, 169.66, 164.39, 161.18, 142.80, 142.64, 142.16, 141.99, 138.05, 137.37, 136.26, 130.65, 130.65-126-71 (11 lines, olefinic), 121.11, 119.48, 119.11, 118.93, 118.68, 118.44, 110.04, 109.74, 109.44, 98.39, 98.04, 97.63, 97.26, 86.11, 86.06, 77.76, 77.21, 76.74, 75.52, 75.25, 74.30, 66.86, 6.10, 4.03; IR (KBr, cm "1) 3434, 2876, 1754, 1718, 1624, 1582, 1454, 1326, 1116, 1086, 738; MS (FAB, MH +) m / z calculated for C53H52F2N307Si 908.3543, observed 908.3547.
Example 15
3,9-difluoro-12, 13-dihydro-13- [6-0- (methylsulfonyl) -β-D-glucopyranosyl] -5H-indolo [2,3-a] pyrrolo [3,4-c] carbazole- 5, 7 (6H) -dione (Ib: Xx = Xlf = F; X2 = X2. = H = R6; R2-R4 = OH; R5 = mesylate)
To a magnetically stirred solution of 3,9-difluoro-12,13-dihydro-13- [β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6H) -dione
(330 mg, 0.630 mmol) in anhydrous pyridine (8 ml) at 0 ° C under nitrogen atmosphere was added by means of a syringe, methanesulfonyl chloride (80 μl, 1.03 mmol). The reaction mixture was stirred at 0 ° C for 3.25 hours and checked periodically by thin layer chromatography on silica gel.
(elution with ethyl acetate) to show the new highest Rf product stain in addition to the initial material. The additional methanesulfonyl chloride (20 μl, 0.26 mmol) was added and the reaction was stirred at 0 ° C for 1.25 hours, and then worked up using ethyl acetate (350 ml) and saturated, aqueous copper (II) sulfate ( 100 ml). The ethyl acetate layer was washed with saturated aqueous copper (II) sulfate (3 x 150 ml), 0.1 N HCl (200 ml), water (200 ml) and brine (200 ml), and dried over sulfate. of sodium. Evaporation in vacuo, followed by flash chromatography on silica gel with 4-6% methanol in dichloromethane, gave 146 mg (39%) of the title compound as a yellow solid: XH NMR at 500 MHz COZY (CD3COCD3) d 10.40 (s, ÍH), 10.00 (s broad, ÍH), 8.97-8.86 (m, 2H), 8.02-7.96 (m, 2H), 7.42-7.33 (m, 2H), 6.43 (d, ÍH, J = 9.2 Hz, l'H), 4.98 (d, ÍH, J = 11.0 Hz, 6'H), 4.76 (d, ÍH, J = 11.0 Hz, 6"H), 4.48 (d, ÍH, J = 10.0 Hz, 5'H), 4.22 (t, ÍH, J = 9.7 Hz, 4'H), 4.00 (t, ÍH, J = 9.3 Hz, 2'H), 3.89 (t, ÍH, J = 9.0 Hz, 3 ' H), 3.23 (s, 3H), mass spectrum FAB, m / e 601 (M +).
Example 16
2, 10-di fluoro-12, 13-dihydro-13- [6-deoxy-6- (1,3-dihydro-1,3-dioxo-2-isoquinolinyl) -β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (A = Ib: Xi = Xlf = F; X2 = X2- = R2 = R6
= h; R2-R4 = OH; R5 = phthalimide).
The potassium phthalimide (0.45 g, 2.43 mmol) was added in one portion to a stirred solution of 2,10-di-fluoro-12, 13-dihydro-13- [6-0- (met ilsul foni 1) -β- D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3,4-c] carbazole-5,7 (6H) -dione (200 mg, 0.33 mmol) in anhydrous dimethylformamide (10 ml) before The mixture was heated at 130 ° C for 3 hours, cooled to room temperature, and concentrated in vacuo overnight. The residue was then taken up in ethyl acetate (some tetrahydrofuran was added) and washed with 0.1 N hydrochloric acid and brine. After drying and concentration of the solvent, the residue was purified by flash chromatography on silica gel (elution with 7% methanol in chloroform) to give the title compound (46 mg, 21%) as a yellow solid. p.f. > 300 ° C; NMR? E (500 MHz, DMSO-d6) d 11.21 (m), 10.80 (s), 9.15-9.13 (m), 9.07-9.02 (m), 7.97 (d, J = 8.8 Hz, ÍH), 7.86 ( d, J «11.1 Hz, ÍH), 7.74-7.69 (m), 7.40 (d, J = 10.3 Hz, ÍH), 7.31-7.23 (m), 7.20-7.17 (m), 6.09 (d, J = 9.1 Hz, ÍH), 5.73 (m), 5.64 (m), 5.30 and 5.26 (2m), 4.99 (m), 4.36-4.27 (m), 4.21 (m), 4.14-4.10 (m), 4.01-3.96 ( m), 3.83-3.72 (2m), 3.57-3.53 (m); IR (KBr, cm "1) 3426, 1752, 1706, 1624, 1579, 1452, 1397, 1328, 1113, 1035; MS (negative ESI, M-H") m / z 651.
Example 17
13- [6- (Azido-6-deoxy-β-D-glucopyranosyl) -2,10-difluoro-12,13-dihydro-5H-indole [2,3-a] pyrrolo [3,4-c] carbazole -5, 7 (6H) -dione (Ib: Xx = Xi »= F; X2 = X2. = H = R6; R2-R4 = OH; R5 = N3).
Sodium azide (0.29 mg, 0.44 mmol) in one portion was added to a stirred solution of 2,10-difluoro-12,13-dihydro-13- [6-0- (methylsulfonyl) -β-D-glucopyranosyl] - 5H-indole [2, 3-a pyrrolo [3,4-c_] carbazole-5, 7 (6H) -dione (132 mg, 0.22 mmol) and powdered molecular sieves of 4 A (50 mg) in anhydrous dimethylformamide ( 3 ml) before the mixture was heated to 60 ° C for 6 hours, cooled to room temperature, diluted with ethyl acetate (some tetrahydrofuran added) and washed with saturated sodium hydrogen carbonate solution and brine. . After drying and concentration of the solvent, the residue was purified by flash chromatography on silica gel
(elution with 10% methanol in chloroform) to yield the title compound (40 mg, 33%) as a yellow solid, decomposition point 265 ° C; NMR XH (500 MHz, DMSO-d6) d 11.89 (broad s, 1H), 11.21 (broad s, ÍH), 11.14 (broad s, ÍH), 10.82 (s, ÍH), 9.19 (dd, J = 8.8 Hz , ÍH), 9.13-9.06 (m, 3H), 7.90
(dd, J = 10.8, 2.1 Hz, HH), 7.71 (dd, J = 10.5, 2.1 Hz, HH), 7.49 (dd, J = 9.6, 2.1 Hz, HH), 7.35 (dd, J = 9.4, 2.3) Hz, ÍH), 7.30-7.22 (m, 4H), 6.33 (d, J -8.7 Hz, ÍH), 6.27 (d, J = 8.6 Hz, ÍH), 5.72 (d, J = 5.2 Hz, ÍH), 5.61 (d, J = 4.9 Hz, ÍH), 5.33 (s broad, ÍH), 5.23-5.21 (m, 2H), 5.11 (d, J = 5.0 Hz, ÍH), 4.20-4.10 (m, 4H), 4.02-3.94 (m, 3H), 3.85-3.83 (m, ÍH), 3.79-3.69 (m, 3H), 3.63-3.58 (m, 3H), IR
(KBr, cm "1) 3422, 2110, 1740, 1700, 1622, 1580, 1450, 1381, 1329, 1231, 1170, 1115, 1074, 829, 763; HRMS
(negative ESI, M-H ") calculated for C26Hi7F2Ns06 547.1256, observed 547.1199.
Example 1
6-amino-13- (6-amino-6-deoxy-β-D-glucopyranosyl) -2, 10-difluoro-12, 13-dihydro-5H-indolo [2,3-a] pyrrolo [3, 4 -c] carbazole-5, 7 (6H) -dione (le: Xi = Xi-F, X2 = X2, = H, R2-R4 = OH, R5 = NH2 = R6).
Hydrazine hydrate (2 ml) was added to 2, 10-difluoro-12,13-dihydro-13- [6-deoxy-6- (1,3-dihydro-1,3-dioxo-2-isoquinolinyl) -β) -D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (19 mg, 0.029 mmol) and the mixture was stirred at room temperature by 1 hour and at 50 ° C for 1 hour, before concentrating in vacuum for 24 hours. Purification of the residue by HPLC on a C? 8 YMC Pack ODS column (30% isocratic flow using methanol / water / 0.1% trifluoroacetic acid) gave the title compound (10 mg, 27%) as an orange yellow solid, pf > 300 ° C; NMR? E (500 MHz, DMS0-d6 / D20) d 8.94-8.89 (2m), 8.81 (m), 8.68 (m), 7.93 (m), 7.82 (d, J = 10.0 Hz, ÍH), 7.73 ( d, J = 10.2 Hz, HH), 7.39 (d, J = 9.5 Hz, 1H), 7.12-7.11 (m), 6.93 (m), 6.20 (d, J = 8.9 Hz, HH), 6.07 (d, J = 7.7 Hz, ÍH), 4.22 (m), 4.16-4.12 (m), 4.14 (t, J = 8.9 Hz, ÍH), 3.79 (t, J = 8.9 Hz, 1H), 3.75-3.73 (m) , 3.61-3.52 (m), 3.40-3.34 (m), 3.31-3.27 (m); IR (KBr, cm "1) 3415, 1757, 1706, 1676, 1623, 1581, 1451, 1404, 1330, 1203, 1112, 839; HRMS (negative ESI, M-H") calculated for C2sH? 9F2N505 536.1460, observed 536.1349.
Example 19
13 -. 13 - [6- (amino-6-deoxy-β-D-glucopyranosyl) -3, 9-difluor or-12, 13-dihydro-5H-indo lo [2, 3-a] pyrrolo [3, 4- c] carbazole-5, 7 (6H) -dione (Ib: Xi = X? < = F; X2 = X2 > = H = R6; R2-R4 = OH; R5 = NH2).
To a solution of the compound 13- [6- (azido-6-deoxy-β-D-glucopyranosyl) -3,9-di-fluoro-12,13-dihydro-5H-indole [2,3-aJpirrolo [3, 4 -c] carbazole-5, 7 (6H) -dione (98.9 mg, 0.180 mmol) in absolute methanol (125 ml) under nitrogen atmosphere in a Parr apparatus, palladium (II) chloride (90 mg, 0.51 mmol ). The mixture was sonicated for 10 minutes and then placed on a Parr shaker at a hydrogen pressure of 4.92 kg / cm2 (70 psi) for 45 hours. The mixture was filtered through a small pad of Celite, washed with methanol and concentrated in vacuo. Purification on Sephadex LH 20 column with elution with methanol (0.4-0.5 ml / minute flow rate), gave 69.6 mg (70%) of the title compound cpmo an orange yellow solid: 500 MHz COZY NMR (d6) -DMSO) d 11.20 (s broad, ÍH), 8.92 (dd, ÍH, J = 9.7, 2.6 Hz), 8.81
(dd, ÍH, J = 9.7, 2.6 Hz), 8.05 (dd, ÍH, J = 9.0, 4.6
Hz), 7.95 (broad s, 3H), 7.88 (dd, ÍH, J = 8.9, 4.6
Hz), 7.48 (ddd, ÍH, J = 2.5, 8.9, 9.1 Hz), 7.41 (ddd,
ÍH, J = 2.5, 8.9, 9.1 Hz), 6.41 (d, ÍH, J = 8.8 Hz, l'H), 5.70 (s broad, ÍH), 5.36 (broad d, 2H, 2 ', 3' OH) , 4.23-4.19 (m, ÍH, 5'H), 4.06-4.02 (m, ÍH, 2'H), 3.89-3.84 (m, ÍH, 3'H), 3.56 (t, ÍH, J = 8.9 Hz , 4'H), 3.32-3.25 (m, ÍH, 6'H), 3.13-3.08 (m, ÍH, 6"H), mass spectrum FAB, m / e 522 (M +).
Example 20
4- [2- (Benzo [b] thien-2-yl) -5-fluoro-lH-indol-3-yl] -3-chloro-l-methyl-lH-pyrrolo-2, 5-dione (V: Xx = 5F; X2 = H = R ': R6 = Me; R "= benzo [b] thienyl, y = Cl).
To a solution of 2- (2-benzo [b] thienyl) -5-fluoroindole
(10.0 g, 0.37 mol) in anhydrous tetrahydrofuran (250 ml) under nitrogen atmosphere was added by means of a syringe ethylmagnesium bromide (3M, 13.1 ml, 0.39 mol) at a rate that maintained the internal temperature between 45-50 ° C. The mixture was then heated to 50-55 ° C for 0.5 hour and cooled again to room temperature before a solution of 3,4-dichloro-1-methylmaleimide (7.41 g, 0.41 mol) in anhydrous tetrahydrofuran was cannulated, to the reaction mixture. The mixture was refluxed for 2 hours, cooled, diluted with ethyl acetate, washed with saturated ammonium chloride solution and with brine, before drying and the concentration of the solvent to 1/4 volume. Filtration by suction of the suspension gave the title compound (12.65 g, 82%) as a red-violet solid, m.p. 250-251 ° C; 1 H NMR (300 MHz, DMSO-ds) d 12.50 (s, ÍH), 8.03-7.99 (m, ÍH), 7.93-7.89 (m, ÍH), 7.83 (s, ÍH), 7.52 (dd, J = 8.9 , 4.4 Hz, HH), 7.46-7.36 (m, 2H), 7.29 (dd, J = 9.9, 2.5 Hz, HH), 7.16-7.09 (m, HH), 3.37 (s, 3H); 13 C NMR (75 MHz, DMSO-d6) ppm 167.71, 165.34, 159.10, 156.00, 139.48, 134.18, 133.76, 133.19, 133.06, 132.66, 127.41, 127.27, 125.20, 125.02, 124.22, 123.64, 122.55, 113.23, 113.10, 111.89 , 111.54, 105.40, 105.07, 100.56, 24.61; IR (KBr, cm "1) 3336, 1778, 1706, 1636, 1490, 1441, 1383,? 297, 1170, 1010, 982, 881, 822, 800, 750, 736; MS (negative ESI, MH") m / z 409. Analysis Calculated for C2? H? 2FN202S: C, 61.39; H, 2.94; N, 6.82. Found; C, 61.08; H, 2.88; N, 6.62.
Example 21
3-f luoro-6-methyl-5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7-dione (VI: Xi = F; X2 =
X = X2 = R '= H; Q = S; R6 = Me).
A suspension containing 4- [2- (benzo [b] thien-2-yl) -5-fluoro-lH-indol-3-yl] -3-chloro-l-methyl-lH-pyrrolo-2, 5 -dione (12.6 g, 30.7 mmol) in anhydrous absolute ethanol / dioxane (60%, 1 liter) was placed in a 2-liter pyrex flask equipped with a reflux condenser. The mixture was stirred and irradiated (Hanovia medium pressure mercury lamp 450 W) for 14 hours before it was cooled to room temperature and refrigerated for an additional 24 hours at -5 ° C. Filtration by suction of the suspension afforded the title compound (12.7 g, 95%) as a glass fiber-like, yellowish green fluorescent solid, m.p. > 305 ° C; NMR XH (500 MHz, DMS0-d6) d 9.50 (d, J = 7.8 Hz, HH), 8.39 (d, J = 9.7 Hz, HH), 8.05 (d, J = 7.8 Hz, HH), 7.55-7.47 (m, 3H), 7.33-7.29 (m, ÍH), 3.55 (s, 0.3 dioxane, 3H), 2.96 (s, 3H); 13 C NMR (125 MHz, DMSO-de at 40 ° C) ppm 168.99, 168.73, 158.05, 138.98, 138.93, 137.97, 134.13, 129.91, 127.73, 127.07, 126.59, 125.40, 125.22, 122.99, 121.18, 118.50, 115.75, 115.55 , 114.81, 112.85, 112.78, 109.87, 109.67, 66.45 (dioxane), 23.66; IR (KBr, cm "1) 3263, 1756, 1702, 1694, 1629, 1494, 1455, 1374, 1291, 1256, 1222, 1168, 1156, 1110, 982, 869, 806, 755, 745, 704, 613; MS (negative ESI, MH ") m / z 373.
Analysis Calculated for C2? HnFN2O2S »0.3dioxane * l .5H20: C, 65.93; H, 3.44; N, 6.93; H20, 0.89. Found: C, 65.86; H, 3.43; N, 6.68; H20, 0.56.
Example 22
3-fluoro-6-methyl-l 3- [2, 3,4,6-tetra-0- (phenylmethyl) -β-D-glucopyranosyl-5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione (VIII: X2 = F; X2 = X = X2- = H; Q = S; R6 = Me; PG = R "'= benzyl) .
Diisopropyl azodicarboxylate (4.6 ml, 24.0 mmol, 4.5 eq.) Was added dropwise to a slightly cool (0 ° C) suspension of 3-fluoro-6-methyl-5H, 13H-benzo [b] thienyl [2 , 3-a] pyrrolo [3,4-c] -carbazole-5,7-dione (2.0 g, 5.34 mmol), 2, 3, 4, 6-tetra-O-benzyl-D-glucopyranose (8.67 g, 16.03 mmol, 3.0 eq.) And triphenylphosphine (6.31 g, 24.0 mmol, 4.5 eq.) In anhydrous tetrahydrofuran (200 ml). The mixture was stirred at 0 ° C for 1 hour before it was diluted with ethyl acetate and washed with 0.1N hydrochloric acid and brine. After drying and evaporation of the solvent, the residue was purified by flash chromatography on silica gel (elution with 10% ethyl acetate in hexanes, followed by 15% ethyl acetate in hexanes) to give the title compound (4.60. g, 96%) as a yellow foam, mp 64-70 ° C; X H NMR (500 MHz, DMSO-de, 1: 1 mixture of rotational isomers) d 9.87 and 9.78 (2m, ÍH), 9.00-8.99 and 8.85-8.83 (2m, ÍH), 8.11-8.02 (2m, 1.5H) , 7.73 (d, J = 7.2 Hz, 0.5H), 7.58-7.54 (m, 2.5H), 7.38-7.23 (m, 15H), 7.18 (d, J = 7.9 Hz, 0.5 H), 6.84 (t, J = 7.4 Hz, 0.5H), 6.78-6.75 (m, 0.5H), 6.67 (t, J = 7.6 Hz, ÍH), 6.55 (t, J = 7.5 Hz, ÍH), 6.51 (d, J = 8.8 Hz, 0.5H), 6.43 (d, J = 9.2 Hz, 0.5H), 6.12-6.10 (m, 2H), 4.95 (d, J = 10.9 Hz, 0.5H), 4.88-4.79 (m, 3H), 4.74-4.65 (m, ÍH), 4.58-4.48 (m, 2.5H), 4.36-4.29 (m, 1.5H), 4.24-4.20 (m, 0.5H), 4.14 (s broad, 0.5H), 4.11- 4.00 (m, 3H), 3.93 (d, J = 10.6 Hz, 0.5H), 3.87 (broad s, HI), 3.18 (s, 3H); IR (KBr, cm "1) 3423, 2920, 2866, 1759, 1699, 1622, 1481, 1453, 1380, 1283, 1255, 1213, 1180, 1160, 1089, 744, 697; MS (FAB, M") m / z 896.
Example 23
3-fluoro-6-methyl-l 3- [β-D-glucopyranosyl] -5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6H diona (la; Xi = F; X2 = X2- = X = H; Q = S; R5 = Me; R2-R5 = OH).
To a cold stirred solution (0 ° C) of 3-fluoro-6-methyl-l 3- [2, 3,4,6-tetra-O- (phenylmethyl) -β-D-glucopyranosyl] -5H, 13H- benzo [b] thienyl [2, 3-a] -pyrrolo [3, 4-c] carbazole-5, 7- (6H) -dione (4.5 g, 5.02 mmol) in ethanethiol (30 ml) was added trifluoride etherate of cold boron (0 ° C) (6.36 ml, 50.2 mmol). The mixture was stirred at 0 ° C for 1 hour before it was allowed to stir at room temperature for a total of 48 hours. Additional boron trifluoride etherate (3.2 ml) was added after 12 hours and 24 hours. The solvent was removed in vacuo and the remaining residue was taken up in ethyl acetate / tetrahydrofuran and washed with 1N hydrochloric acid and brine, before drying and concentration of the solvent. Purification of the residue by flash chromatography on silica gel (gradient elution with 10% methanol in chloroform followed by 15% methanol in chloroform) afforded the title compound (2.53 g, 94%) as a yellow solid, m.p. > 305 ° C; NMR XH (500 MHz, DMSO-d6) d 9.85 and 9.71 (2d, J = 7.4 and 7.5 Hz, ÍH), 8.96 and 8.89 (2d, J = 9.6 and 9.6 Ha, ÍH), 8.13-8.05 (m, 1.25 H), 7.99 (dd, J = 9.0, 4.5 Hz, 0.75H), 7.61-7.41
(3m, 3H), 6.29 and 6.09 (2d, 8.8 and 9.3 Hz, ÍH), 5.36- 5.33 (3H), 4.84-4.72 (m, 1.5H), 4.04-3.98 (m, ÍH),
3. 92-3.86 (m, 1.75H), 3.76-3.68 (m, 2H), 3.63-3.54 (m, 1.75H), 3.16 (s, 3H); 13 C NMR (125 MHz, DMSO-d 6) ppm 169.34, 169.19, 169.04, 158.81, 156.95, 140.06,
138. 48, 137.05, 133.12, 131.70, 131.49, 130.85,
129. 75, 128.36, 127.40, 127.20, 126.52, 125.78,
125. 71, 125.39, 122.80, 122.66, 122.35, 119.81, 116.33, 116.08, 115.94, 115.74, 110.70, 110.50,
105. 28, 87.77, 81.36, 77.72, 70.89, 69.86, 61.28,
24. 33; IR (KBr, cm "1) 3428, 1756, 1694, 1622, 1481,
1460, 1448, 1384, 1084, 745; MS (negative ESI, M-H ") m / z 535.
Example 24
3-fluoro-13- (β-D-glucopyranosyl) -5H, 13H-benzo [b] -thienyl [2,3-a] pyrrolo [3,4-c] carbazole-5,7 (6H) -dione ( the: R2-R5 = OH, R6 = X2 = Xv = X2- = H, Q = S).
3-Fluoro-6-methyl-l 3- (β-D-glucopyranosyl) -5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 ( 6H) -dione (0.20 g, 0.37 mmol) was suspended in a potassium hydroxide solution 10% aqueous (30 ml) under nitrogen atmosphere. The mixture was heated to reflux gently for 3 hours before it was titrated with concentrated hydrochloric acid until a dense precipitate formed. The precipitate was taken up in ethyl acetate / tetrahydrofuran and washed with 1N hydrochloric acid and brine before drying and concentration of the solvent. The residue was dissolved in absolute methanol (1 ml) and solid ammonium acetate (3.0 g) was added. The mixture was melted at 150 ° C for 3 hours before it cooled, was diluted with ethyl acetate / tetrahydrofuran, washed with 1 N sodium hydroxide with brine, dried and concentrated. Purification of this residue by flash chromatography on silica gel (gradient elution with 30% tetrahydrofuran in chloroform followed by 50% tetrahydrofuran in chloroform) afforded the title compound (69.5 mg, 36%) as a yellow solid, m.p. >305 ° C; NMR XH (500 MHz, DMSO-d6) d 11.67 (s, 0.25H), 11.53 and 11.51 (2s, ÍH), 9.95-9.93 and 9.91-9.89 (2m, ÍH), 0.02 and 8.97 (2dd, J = 9.8 , 2.7 Hz and 9.7, 2.8 Hz, ÍH), 8.24-8.23 and 8.18-8.16 (2M, ÍH), 8.08 and 8.01 (2dd, J = 9.4 4.4 Hz and 9.1, 4.6 Hz, ÍH), 7.69-7.63 (m , 2H), 7.54-7.48 (m, ÍH), 6.34 and 6.09 (2d, J = 8.9, 9.4 Hz, ÍH), 5.37-5.35 (m, ÍH), 5.28 and 5.22 (2m wide, 2H), 4.75 ( m broad, 0.75H), 4.04 and 3.87-3.75 (2m, 3H), 3.68-3.58 (, 2H), 3.55-3.52 (m, 2H); 13 C NMR (125 MHz, DMSO-d 6) ppm 170.39, 170.16, 158.76, 156.89, 140.05, 138.34, 136.87, 133.09, 131.76, 128.32, 127.28, 126.62, 125.64, 122.64, 120.60 > • 116.16, 115.95, 115.84, 110.76, 110.56, 107.35, 87.71, 81.13, 77.45, 70.74, 69.79, 67.01, 61.23; IR (KBr, cm "1) 3392, 1747, 1705, 1625, 1481, 1462, 1430, 1326, 1284, 1262, 1180, 1087, 804, 758, 747; HRMS (negative ESI, MH") calculated for C2eH? 8FN207S 521.0897, observed 521.0802.
Example 25
3, 9-di-fluoro-12, 13-dihydro-13- [3, 6-0- (t-but i Idime ti 1-silyl) -β-D-glucopyranosyl] -5H-indole [2, 3-a ] pyrrolo- [3, 4-c] carbazole-5, 7 (6N- [4- (t-but i 1) benzyl] -) -dione (Ib: Xa = Xv = F; X 2 = X 2 - = H; R6 = 4- (t-butyl) benzyl, Q = NH, R2 = R4 = OH, R3 = R5 = t-butyldimethylsilyloxy).
To a magnetically stirred solution of the product of Example 12 (750 mg, 1.12 mmol) and imidazole (1.9 g, 28 mmol) in anhydrous dimethylformamide (14 mL) under nitrogen with stirring, trifluoromethanesulfonate was added via a syringe. of t-butyldimethylsilyl (2.96 g, 2.57 ml, 11.2 mmol). The reaction was stirred at room temperature for 1 hour and quenched with absolute ethanol (5 ml). The mixture was diluted with ethyl acetate (150 ml) and washed with water (6 x 100 ml), and brine (100 ml), and dried over sodium sulfate. This material was used directly in the next step without further purification. The analytical sample was purified by flash chromatography on silica gel with hexane / methylene chloride: 300 MHz tE NMR (CDC13) d 10.06 (broad s, ÍH), 9.12 (dd, ÍH, J = 9.2, 2.7 Hz), 7.88-7.81 (m, ÍH), 7.72 (dd, ÍH, J = 9.2, 3.9 Hz), 7.41 (ddd, ÍH, J = 8.9, 8.9, 2.6 Hz), 7.25 (dd, ÍH, J = 9.0, 4.1 Hz), 7.20-6.99 (m, 4H), 6.92 (ddd, ÍH, J = 8.7, 8.7, 2.4 Hz), 5.97 (d, ÍH, J = 8.9 Hz), 4.58-3.90 (m, 8H), 1.18 (s, 9H), 0.91 (s, 9H), 0.83 (s, 9H), 0.27 (s, 3H), 0.10 (s, 3H), 0.05 (s, 3H), -0.02 (s, 3H); mass spectrum FAB, m / e 897 (M +).
Example 26
3, 9-difluoro-12, 13-dihydro-13- [3-0- (t-butyldimethyl-silyl) -β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo- [3 , 4-c] carbazole-5, 7 (6N- [4- (t-butyl) benzyl] -) -dione (Ib: Xa = Xv = F; X2 = X2- = H; R6 = 4- (t -butyl) benzyl, Q = NH, R 2 = R 4 = OH, R 3 = t-butyldimethylsilyloxy).
To a magnetically stirred solution of the crude product of Example 25 at -5 ° C was added a mixture of trifluoroacetic acid: water 9: 1 precooled at -5 ° C. The reaction was stirred at -5 ° C for 45 minutes, diluted with ethyl acetate (200 ml), and washed with saturated sodium hydrogen carbonate solution (6 x 150 ml), with water (1 x 150 ml) , and brine (1 x 150 ml), and dried over sodium sulfate. Evaporation in vacuo, followed by flash chromatography on silica gel with 1-10% methanol in methylene chloride gave 59 mg (6%) of the starting material (eg compound of Example 25), 78 mg (10%) of the completely desilylated product (for example compound of Example 12), and 585 mg (74%) of the pure title compound as a yellow solid: XH NMR at 500 MHz COZY (d6-DMSO) d 11.80 (broad s, ÍH), 8.82 (dd, ÍH, J = 9.6-2.7 Hz), 8.76 (dd, ÍH, J = 9.7, 2.7 Hz), 8.03 (dd, ÍH, J = 9.2, 4.4 Hz), 7.68 (dd, ÍH, J = 8.9, 4.5 Hz), 7.51-7.45 (m, 2H), 7.38-7.31 (m, 4H), 6.28 (d, ÍH, J = 9.1 Hz, l'H), 6.08 (t, ÍH, J = 3.9 Hz , 6'0H), 5.35 (d, ÍH, J = 6.8 Hz, 4'0H), 4.88 (s, 2H), 4.81 (d, ÍH, J = 6.8 Hz, 2'0H), 4.12-4.08 (, ÍH, 6'H), 3.98-3.93 (m, ÍH, 5'H), 3.93-3.90 (m, ÍH, 4'H), 3.86-3.82 (m, ÍH, 6'H), 3.73 (t, ÍH, J = 8.8 Hz, 3'H), 3.39 (ddd, ÍH, J = 9.1, 8.8, 6.8 Hz, 2'H), 1.23 (s, 9H), 0.76 (s, 9H), 0.07 (s, 3H), -0.03 (s, 3H); mass spectrum m / e 783 (M +).
Example 27
3, 9-difluoro-12, 13-dihydro-13- [3-0- (t-butyldimethyl-silyl) -6-0- (methanesulfonyl) -β-D-glucopyranosyl] -5H-indo lo [2, 3-a] pyrrolo (3,4-c] carbazole-5, 7 (6N- [4- (t-butyl) benzyl] -) -dione (Ib: X x = X v = F; X 2 = X 2 - = H; R6 = 4- (t-butyl) benzyl, Q = NH, R 2 = R 4 = OH, R 3 = t-butyldimethylsilyloxy, R 5 = methanesulfonyloxy)
To a magnetically stirred solution of the pure product of Example 26 (403 mg, 0.514 mmol) in anhydrous pyridine (7 ml) at -10 ° C under an argon atmosphere was added via a syringe in 1 minute, methanesulfonyl chloride (46 g. μl, 0.594 mmol). After 70 minutes at -10 ° C, an aliquot was removed, added to a mixture of ethyl acetate and saturated aqueous copper (II) sulfate, and analyzed by thin layer chromatography on silica gel using 1-2 % methanol in methylene chloride. It appeared mainly indicated the initial material by a small amount of the stain of the product of higher Rf. Additional methanesulfonyl chloride (32 μl) was added and the reaction was maintained at -10 ° C for 1 hour. In 30 minute intervals, the reaction was treated successively with additional methanesulfonyl chloride (33 μl, 31 μl, 31 μl and 24 μl). After a total of 5 hours at -10 ° C, thin layer chromatography showed the largest product spot and a little of the initial material of the lowest Rf. In the last 1.5 hours, the temperature of the reaction was allowed to rise to -1 ° C from -10 ° C. The reaction mixture was quenched by the addition of 200 μl of absolute ethanol, stirred for 5 minutes, and partitioned with ethyl acetate (600 ml) and saturated aqueous copper (II) sulfate (250 ml). The organic layer was washed with saturated aqueous copper (II) sulfate (200 ml), water (200 ml) and brine (200 ml), and dried over sodium sulfate. Evaporation in vacuo, followed by flash chromatography on silica gel with 1% methanol in methylene chloride gave 404 mg (91%) of the pure title compound and 40 mg of the recovered starting material: XH NMR at 300 MHz, (CDC13 ) d 9.83 (s broad, ÍH), 9.08 (dd, ÍH), 7.80-7.71 (m, ÍH), 7.68 (dd, ÍH), 7.52 (dd, ÍH), 7.40 (ddd, ÍH), 7.21-7.13 (m, 2H), 7.03-6.86 (m, 3H), 5.94 (d, ÍH), 5.15-3.92 (m, 10H), 3.02 (s, 3H), 1.19 (s, 9H), 0.84 (s, 9H) ), 0.23 (s, 3H), -0.01 (s, 3H); mass spectrum FAB, m / e 861 (M +.
Example 28
3, 9-difluoro-12, 13-dihydro-13 - [3 -O- (t-but i Idimeti 1-silyl) -6- (4N-morpholino) -β-D-glucopyranosyl] -5H-indolo [ 2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6N- [4- (t-butiD-benzyl] -) -dione (Ib: Xi = Xv = F; X2 = X2 < = H; R6 = R- (t-butyl) benzyl; Q = NH; R2 = R4 = OH; R3 = t-butyldimethylsilyloxy; R5 = morpholino)
To a magnetically stirred solution of the pure product of Example 27 (193 mg, 0.224 mmol) in anhydrous DMSO (5 mL) under nitrogen atmosphere was added morpholine (210 μL, 2.41 mmol). The resulting red reaction mixture was stirred for 69 hours at 47 ° C and partitioned with ethyl acetate (350 ml) and saturated aqueous sodium hydrogen carbonate solution (75 ml). The organic layer was washed with water (4 x 70 ml) and brine (75 ml), and dried over sodium sulfate. Evaporation in vacuo, followed by flash chromatography on silica gel with 20-25% ethyl acetate in methylene chloride gave 9 mg (5%) of the recovered starting material and then 102 mg (53%, 56% based on the initial material recovered) of the pure title compound as a yellow solid: 2 H NMR at 300 MHz, (CDC13) d 10.03 (broad s, HI), 9.09 (dd, ÍH), 8.02-7.96 (m, 1H), 7.69 (dd, ÍH), 7.39 (ddd, ÍH), 7.30-7.23 (m, ÍH), 7.21-7.17 (m, 2H), 7.07-6.98 (m, 3H), 5.96 (d, ÍH), 4.53-3.93 (m, 6H), 3.72-3.57 (m, 4H), 3.19-2.98 (, 2H), 2.82-2.71 (m, 2H), 2.68-2.58 (m, 2H), 1.19 (s, 9H), 0.88 ( s, 9H), 0.27 (s, 3H), 0.08 (s, 3H); ESI (NEGATIVE) mass spectrum, m / e 851 (M-H) ".
Example 29
3, 9-difluoro-12, 13-dihydro-3- [6- (4N-morphino) -β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] ] carbazole-5, 7 (6H) -dione (la: Xi = Xv = F; X2 = X2- = R6 = H; R5 = 4N-morpholino; Q = NH; R2-R4 = OH).
To a magnetically stirred solution of the pure product of Example 28 (205 mg, 0.240 mmol) in absolute ethanol (160 mL) was added aqueous potassium hydroxide (4.45 M, 42 mL, 187 mmol). The resulting dark red solution was heated in an open flask until all the ethanol was evaporated and a solid gum was obtained (approximately 1.5 hours). The mixture was cooled under a stream of nitrogen and concentrated hydrochloric acid (12 N, 17 mL, 204 mmol) was added. The mixture was stirred 5 minutes and absolute ethanol (90 ml) was added, followed by solid ammonium acetate (85 g). The mixture was heated with stirring in an open flask just below the boiling point, for 2.5-3 hours and then at 180 ° C (internal melt temperature) in about 2 hours. The mixture was further heated to 200 ° C in 10-15 minutes, cooled rapidly under a stream of nitrogen to about 50-60 ° C, and digested with water (200 ml), with saturated aqueous sodium carbonate solution (200 ml), and with ethyl acetate (800 ml). The organic layer was washed with brine (200 ml), the combined aqueous layers were extracted with fresh ethyl acetate (300 ml), and the last extract was washed with brine (100 ml). The combined organic extracts were dried over sodium sulfate and evaporated in vacuo. The crude material was dissolved in methanol (400 ml) and treated with anhydrous potassium carbonate (2.0 g) and potassium fluoride dihydrate (1.03 g), and stirred at room temperature for 15 hours. The solvent was evaporated in vacuo, the residue redissolved in methanol (250 ml), treated with 1 N hydrochloric acid (15 ml), and evaporated in vacuo. The residue was dissolved in absolute ethanol (500 ml), evaporated in vacuo, and this process was repeated again. Recrystallization from 95% ethanol gave 79.6 mg (53%, 2 crops) of the pure title compound as its hydrochloride salt: NMR? E at 500 MHz, COZY (d6-DMSO) d 12.67 (broad s, ), 11.19 (s, 1H), 8.92 (dd, ÍH, J = 9.7, 2.6 Hz), 8.79 (dd, ÍH, J = 9.8, 2.3 Hz), 8.05 (dd, ÍH, J = 9.0, 4.5 Hz) , 7.94 (dd, ÍH, J = 8.7, 4.5 Hz), 7.46 (ddd, ÍH, J = 2.5, 8.9, 9.0 Hz), 7.41 (ddd, ÍH, J = 2.6, 9.0, 9.1 Hz), 6.61 (d , HH, J = 8.6 Hz, HH), 3.97 (t, HH, J = 8.8 Hz, 2'H), 3.91-3.16 (m, 13H).
Example 30
3, 9-difluoro-12, 13-dihydro-13- [6-azido-β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 ( 6-hydroxy) dione (le)
To a magnetically stirred solution of 3,9-difluoro-12,13-dihydro-13- [6-azido-β-D-glucopyranosyl] -5H-indole [2, 3-a] pyrrolo [3, 4-c] ] carbazole-5, 7 [6 (4-t-butylbenzyl)] -dione (20 mg, 0.029 mmol) in absolute ethanol (5 ml) was added aqueous potassium hydroxide (4.45 M, 1.1 ml, 4.9 mmol). The resulting dark red solution was heated in an open flask until all the ethanol was evaporated and a solid gum formed (approximately 1.5 hour). This mixture was cooled under a stream of nitrogen and absolute ethanol (5 ml) was added, followed by solid hydroxylamine hydrochloride (685 mg). The mixture was heated to reflux with stirring for 4 hours, then heated to 110 ° C (internal temperature of the melt after the boiling solvent) for about 3 hours. The mixture was cooled under a stream of nitrogen at room temperature, and digested with 1 N HCl (80 ml) and ethyl acetate (400 ml). The organic layer was washed with 1 N hydrochloric acid (3 x 50 ml), water (2 x 50 ml), and brine (100 ml), and dried over sodium sulfate, evaporation in vacuo, followed by purification on a Sephadex LH 20 column with elution with methanol 0.4-0.5 ml / minute flow rate) gave 4.3 mg (27%) of the title compound as a yellowish red solid: IR (KBr) 2114 cm "1; XH NMR at 500 MHz COZY (CD3OD) d 8.53 (dd, ÍH, J = 9.6, 2.1 Hz), 8.36 (dd, ÍH, J = 9.5, 1.9 Hz), 7.68 (dd, ÍH, J = 8.8, 3.7 Hz ), 7.36 (dd, ÍH, J = 8.8, 4.2 Hz), 7.24 (ddd, ÍH, J = 8.7, 8.7, 2.0 Hz), 7.14 (ddd, 1H, J = 8.9, 8.8, 2.3 Hz), 5.98 ( d, ÍH, J = 9.0 Hz, l'H), 4.47 (d, ÍH, J = 12.1 Hz, 6'H), 4.28 (d, ÍH, J = 12.1 Hz, 6"H), 4.11 (d, ÍH, J = 9.4 Hz, 5'H), 3.91 (t, ÍH, J = 9.4 Hz, 4'H), 3.61 (t, ÍH, J = 9.0 Hz, 2'H), 3.46 (dd, ÍH, J = 9.4, 9.0 Hz, 3'H), mass spectrum FAB, m / e 564 (M +).
Example 31
3, 9-difluoro-12, 13-dihydro-13- [6-amino-β-D-glucopyranosyl] -5H-indolo [2,3-a] pyrrolo [3,4-c] carbazole-5, 7 (6-hydroxy) dione (le) To a solution of the product of Example 30 (3.0 mg, 0.0053 mmol) in absolute methanol (2 ml) under nitrogen atmosphere in a Parr apparatus was added palladium (II) chloride (15 mg , 0.09 mmol). The mixture was sonicated for 10 minutes and then placed on a Parr shaker at 4.57 kg / cm2 (65 psi) of hydrogen pressure for 24 hours. The mixture was filtered through a small pad of Celite, washed with methanol, and concentrated in vacuo to give 2.0 mg (66%) of the title compound as a yellowish orange solid: mass spectrum FAB, m / e 538 (M +). Additional examples of compounds of formula I, which can be synthesized by modifications of the above synthetic methods, are described in Table IV, wherein the substituents are the same as in Example 29 unless mentioned above. another way.
Table IV
E j emp l o R2 R5 R6 O
Do not . 32 OH N3 4 -t-butyl-? H benzyl Table IV
E j emplo R Rs RÉ O No. 33 OH N3 H NH
34 OH imidazole H NH
OH 4-Me-piperazine H 'NH
36 OH 4N-morpholino H S
37 OH NH2 H S
38 OH 4N-morpholino H O
39 OH NH2 H O
40 OH N3 H O
41 OH N (CH2CH2OH) 2 H S
42 OH CN H S
43 OH COOH H NH
44 OH N? ORNITHINE H NH
45 0 OH H NH
46 N-OH OH H NH
47 OH R H NH
48 OH F OH NH
The analytical data for some of the Examples shown in Table IV are given below:
Example 32: IR (KBr) 2110 c "1; XH NMR at 500 MHz COZY (CD3OD) d 8.81-8.8.79 (m, 2H), 7.68 (dd, ÍH, J = 9.1,
4. 0 Hz), 7.56 (dd, ÍH, J = 8.8, 4.2 Hz), 7.38-7.25
(m, 6H), 6.05 (d, ÍH, J = 8.5 Hz, l'H), 4.75 (s, 2H), 4.29 (d, ÍH, J = 12.8 Hz, 6'H), 4.17-4.06 (m , 2H,
', 6"H), 4.00 (t, ÍH, J = 8.9 Hz, 4'H), 3.70-3.65 (m,
2H, 2'3'H), 1.27 (s, 9H); mass spectrum FAB, m / e
694 (M +).
Example 33: Yellow solid: IR (KBr) 2112, 1750, 1700 cm "1; XH NMR at 500 MHz COZY (CD30D) d 8.78-8.72 (m, 2H), 7.77 (dd, ÍH, J = 9.1, 4.1 Hz ), 7.55 (dd, ÍH, J = 8.8, 4.2 Hz), 7.33-7.26 (m, 2H), 6.12 (d, ÍH, J = 8.5 Hz, l'H), 4.27 (d, ÍH, J = 11.5 Hz, 6'H), 4.15-4.07 (, 2H, 5 ', 6"H), 4.01 (t, ÍH, J = 8.7 Hz, 4'H), 3.74-3.67 (, 2H, 2', 3 ' H); mass spectrum FAB, m / e 548 (M +).
Example 34: Yellow-orange solid: 500 MHz XH NMR, CD3OD) d 8.81-8.61 (m, 2H), 7.88-7.04 (m, 7H),
6. 32 (d, ÍH, J = 8.9 Hz, l'H), 4.20-3.30 (m, 6H); mass spectrum FAB, m / e 574 (MH +).
Example 35: Yellow solid; mass spectrum FAB, m / e 605 (M +).
Example 36: Yellow solid, m.p. 257-2730C; NMR? E (500 MHz, DMSO-d6) d 11.73 (broad s, ÍH), 9.53-9.40 (2m, ÍH), 8.65-8.63 (m, ÍH), 8.25-7.91 (4m, 2H), 7.52-7.25 (3m, 2H), 6.21 and 6.10 (2d, J = 8.8, 9.3 Hz, ÍH), 5.47-4.99 (series of m, 3H), 4.10-3.86 (3m, 3H), 3.56-3.53 (m, 7H) , 2.99-2.57 (series of m, 4H); IR (KBr, cm "1) 3412, 2924, 2800, 1706, 1653, 1602, 1567, 1481, 1463, 1425, 1321, 1301, 1198, 1110, 1067, 916, 804, 764, 742; MS (+ ESI) , M + H +) m / z 610.
Example 37: 12 - [6-amino-6-deoxy-β-D-glucopyranosyl) -3-fluoro-5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 (6H) -dione
Triphenylphosphine (107 mg, 0.41 mmol) was added in one portion to a stirred solution of 12- [6- (azido-6-deoxy-β-D-glucopyranosyl) -3-fluoro-5H, 13H-benzo [b] thienyl. [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7 (6H) -dione (75 mg, 0.14 mmol) in wet tetrahydrofuran
(3 ml) under nitrogen atmosphere before the mixture was heated to 50 ° C for 28 hours, cooled to room temperature and treated with aqueous solution of ammonium hydroxide for 1 hour at room temperature and for 1 hour at 50 hours. ° C. After cooling to room temperature, the mixture was concentrated in vacuo and the residue was taken up in methanol, acidified with 1 N HCl / Et20 and evaporated to dryness. Purification of this residue by HPLC on a YMC Pack ODS column (20x100) operating at 87% B, afforded the title compound (54 mg, 71%) as a yellow solid, decomposition point 290 ° C (sealed tube); NMR? E (500 MHz, DMSO-d6) d 11.55 (s broad, ÍH), 9.94-9.90 (m, ÍH), 9.03-8.96 (2m, ÍH), 8.30-8.26 (m, 4H), 8.12-8.08 (m, ÍH), 7.71-7.29 (series of m, 6H), 6.36 and 6.15 (2d, J = 8.9, 9.3 Hz, ÍH), 5.81 and 5.55 (2m, 2H), 4.23-3.70 (5m, 2H) , 3.60-3.57 and 2.94 (2m, 2H), 1.68-1.41 (3m, 2H); IR (KB r, cm "1) 3401, 1702, 1624, 1482, 1460, 1328, 1284, 1209, 1182, 1087, 757, 746; MS (FAB, MH +) m / z 522.
Example 39
3, 9-di-fluoro-12- (6 -ami non-6-deoxy-β-D-glucopyranosyl) benzofurane [2, 3-a] -pyrrolo [3,4-c] -carbazole-5, 7- diona
To a magnetically stirred solution of 3,9-di-fluoro-12- (β-D-glucopyranosyl] benzofuran [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7-dione (50 mg, 0.09 mmol) and powdered molecular sieves of 4 angstrom (100 mg) in anhydrous pyridine (3 ml) at -30 ° C under an argon atmosphere, methanesulfonyl chloride (10 μl, 0.12 mmol) was added via syringe. The reaction mixture was stirred at -30 ° C for 1 hour, then at -10 ° C for 0.5 hours followed by an additional portion of methanesulfonyl chloride (10 μL, 0.12 mmol) This resulting mixture was then stirred at 0 ° C. for 1 hour, it was filtered by suction and concentrated.The residue was taken up in ethyl acetate / tetrahydrofuran and washed with water, dried over sodium sulfate and evaporated.The resulting residue was washed with toluene to give a yellow product. crude oil which was used directly for the next reaction-without further purification.Sodium azide (62 mg, 0.95 mmol) was added to a stirred solution of 3,9-difluoro-12- (6-0- (methylsul fonyl) -β-D-glucopyranosyl) benzo furan- [2,3-a] pyrrolo [3,4- c] -carbazole-5, 7-dione (54 mg, 0.09 mmol) in anhydrous dimethylformamide (3 ml) before the mixture was heated to 70 ° C for 1 hour. The reaction mixture was cooled to room temperature, diluted with water, dried over sodium sulfate and concentrated in vacuo. The crude yellow product was used directly for the next reaction without further purification. A mixture of 3,9-difluoro-12- (6-azido-deoxy-β-D-glucopyranosyl) benzofuran- [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione (Example 40) (49 mg, 0.09 mmol) and 10% palladium on carbon (50 mg) in a mixture of ethanol (3 ml) and tetrahydrofuran (1 ml) was hydrogenated at 1 atmosphere for 21 hours. The reaction mixture was filtered, washed with methanol and tetrahydrofuran, and concentrated in vacuo. The crude product was subjected to chromatography (60% methylene chloride: 20% tetrahydrofuran and 20% a solution of 90% methanol and 10% ammonium hydroxide) to provide the title compound (20 mg, 42% ) as a yellow solid: IR (KBr) 1753, 1701, 1479 cm "1: XH NMR (DMSO-d6, 400 MHz) d 8.87-8.82 (m, HH), 8.56-8.49 (m, HH), 8.10- 7.99 (m, 2H), 7.67-7.50 (m, 2H), 6.53 (d, 0.7 H, J = 9.0 Hz), 6.14 (d, 0.3H, J = 9.0 Hz), 5.44-5.30 (m, 2H) , 4.28-2.86 (m, 7H): HPLC: 90.4% (247 nm).
Example 45: XH NMR at 300 MHz d6-acetone) d 11.97 (broad s, ÍH), 9.91 (s, ÍH), 9.12 (dd, ÍH), 8.88 (dd, ÍH), 7.92 (dd, ÍH), 7.69 (dd, ÍH) 7.47-7.23 (m, 2H), 7.48 (ddd, ÍH, J = 2.5, 8.9, 9.1 Hz), 7.41 (ddd, ÍH, J = 2.5, 8.9, 9.1 Hz), 6.73 (s, ÍH, l'H), 4.60-3.95 (m, 6H).
Example 47:
Yellow-orange solid: 500 MHz 1E NMR (CDC13 with one drop of d6-DMSO) d 10.36 (d, HH, JH-F = 4.2 Hz), 9.98 (broad s, HH), 8.81 (dd, HH, J = 9.5, 2.6 Hz), 8.68 (dd, ÍH, J = 9.5, 2.5 Hz), 7.47 (dd, ÍH), 7.30-7.40 (m, ÍH), 7.15-7.04 (, 2H), 5.84 (d, ÍH) , J = 8.5 Hz), 5.02 (dd, ÍH, JH-F = 45.2 Hz, JH-H = 10.1 Hz), 4.72 (dd, ÍH, JH-F = 49.6 Hz, JH-H = 10.1 Hz), 4.03 -3.82 (m, 2H), 3.71-3.60 (, 2H); ESI negative mass spectrum, m / e 524 (M-H) -.
Example 48: H-NMR at 500 MHz (d6-DMSO) d 8.80-7.20 (m, 6H), 6.38 (d, ÍH), 5.15-3.45 (, 6H). mass spectrum (ESI (NEG), m / e 540 (M-H) ".
Additional examples of the compounds of formula I, which can be synthesized by modifications of the above synthetic procedures, are described in Table V, wherein the substituents are the same as in Example 19 unless mentioned above. another way.
Table V
E jmplo í Rs O
No. 49 OH Cl H NH
50 OH Cl H S
51 OH Cl H O
52 OH F H S
53 OH F H O
54 OH SCH3 H NH
55 OH SCH3 H S
56? OH N3 N S
57 OH S (0) CH3 H S 8 OH S (0) CH3 H NH
59 OH SCH2COOH H NH
60? OH l-piperidine H S
61? OH Tiomorf olin-S-HS oxide 2 OH S- (2-pyridine) HS 3 OH S- (2-pyridine-N-HS oxide) 64 OH S- (2- (4-OH) - H pyrimidinyl) 5 OH SCH2CF3 HS 6 OH S (0) CH2CF3 HS Table V (continued)
E j emplo R * * 1 1 No. 67 OH S- (2- -imidazole) H S
68 OH Net2 OH NH
69 OH F OH S 0 N3 F H NH 1 + R 4 = = R 4 'OH H NH
= F 2 F F H NH 3 NH 2 F H NH 4 CH 3 F H NH 5 N 3 H H NH 6 * R 4 = = R 4 'OH H NH = 0 7 R 4 = = R 4' F H NH
-H 8 OH -CH 2 CH 2 NH-NH (-C (NH) NH 2) 9 NH 2 H H NH 0 F H H NH 1 R 4 = R 4 'H H 0 -F Table V (continued)
Example k R * No. 82 R4 = R4 'HH = F 83 FHHS 84 CH3 FHS 85 OCH3 FHS 86 OCH3 FH NH 87 N3 OH H NH 88 NH2 OH H NH Note that in Examples 56, 60 and 61, X'i It is hydrogen. Note that in Example 89, X2 and X'2 are, respectively 2- and 10-fluoro, also R5. and R5- taken together is = 0. Note that in Examples 71 and 76, X2 and X'2 are respectively 2- and 10-fluoro.
The analytical data for some of the examples shown in Table V are given below.
Example 50: yellow solid, m.p. 242-248 ° C decomposes; NMR XH (500 MHz, DMS0-d6) d 11.55 (broad m, ÍH), 9.75-9.57 (2m, ÍH), 9.01-8.87 (2m, ÍH), 8.23-7.98 (3m, 2H), 7.57-7.34 ( 2m, 2H), 6.33 and 6.21 (2d, J = 8.8, 9.4 Hz, ÍH), 5.69-5.61 (2m, ÍH), 5.44-5.17 (2m, 2H), 4.12-3.96 (, 4H), 3.66-3.55 (2m, 2H); IR (KBr, cm "1) 3392, 2926, 1703, 1622, 1602, 1567, 1481, 1463, 1426, 1324, 1198, 1085, 915, 806, 763, 742; MS (-ESI, MH") m / z 557.
Example 52: yellow solid, m.p. 248-250 ° C; H NMR (500 MHz, DMSO-dβ) d 11.73, 11.65 and 11.62 (3s, ÍH), 9.81-9.68 (2m, ÍH), 9.07-8.99 (2m, ÍH), 8.27-8.00 (m, 2H), 7.61 -7.50 (m, ÍH), 6.38 and 6.26 (2d, J = 8.8, 9.3 Hz, ÍH), 5.69-5.21 (series of m, 3H), 5.05-4.82 (m, 2H), 4.25-3.82 (m, 2H), 3.72-3.61 (m, ÍH); IR (KBr, cm "1) 3384, 1706, 1622, 1602, 1568, 1481, 1463, 1325, 1198, 1086, 916, 806, 763, 742; MS (-ESI, M-H") m / z 541.
Example 54: 300 MHz * H NMR (CD3OD) d 8.80 (dd, 1H, J = 9.6, 2.3 Hz), 8.72 (dd, 1H, J = 9.9, 2.8 Hz), 7.84-7.73 (m, 2H), 7.37-7.26 (m, 2H), 6.15 (d, ÍH, J = 9.5 Hz), 4.34-4.27 (m, ÍH), 4.14 (t, ÍH, J = 9.5 Hz), 3.97 (t, ÍH, J = 9.0 Hz), 3.74 (t, ÍH, J = 9.0 Hz), 3.45 (dd, ÍH, J = 14.8, 1.8 Hz), 3.15 (dd, ÍH, J = 14.8, 3.9 Hz), 2.19 (s, 3H); ESI negative mass spectrum, m / e 552 (M-H).
Example 56
12- [6- (Azido-6-deoxy-β-D-glucopyranosyl) -3-fluoro-5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3, 4-c] carbazole-5 , 7 (6H) -dione.
Sodium azide (216 mg, 3.30 mmol) was added in one portion to a stirred solution of 3-fluoro-13- [6-0-. { methylsulfonyl) -β-D-glucopyranosyl] -5H, 13H-benzo [b] thienyl [2, 3-a] pyrrolo [3,4-c] carbazole-5,7 (6H) -dione (0.20 g, 0.33 mmol ) in anhydrous dimethylformamide
(3 ml) before the mixture was heated to 120 ° C for 3 hours, cooled to room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (elution with 40% tetrahydrofuran in hexanes) to give the title compound (141 mg, 78%) as a yellow solid, decomposition point 265 ° C; NMR JH (500 MHz, DMSO-d6) 8 11.51 (broad s, ÍH), 9.94-9.87 (2m, ÍH), 9.03-8.95 (2m, ÍH), 8.20-7.99 (3m, 2H), 7.67-7.63 ( m, 2H), 7.53-7.49 (m, ÍH), 6.37 and 6.20 (2d, J = 8.9 and 9.4 Hz, ÍH), 5.54-5.14 (series of m, 3H), 4.10-3.76 (4m, 3H), 3.67-3.26 (m, 3H); IR (KBr, cm "1) 3332, 2103, 1702, 1481, 1461, 1431, 1372, 1324, 1283, 1230, 1211, 1178, 1079, 746; MS (-ESI, M-H") m / z 546.
Example 57
Yellow solid, m.p. 268-277 ° C (decomposes); NMR XH (500 MHz, DMSO-d6) d 11.52 (broad s, ÍH), 9.75-9.51 (3m, ÍH), 9.00-8.88 (2m, ÍH), 8.30-7.97 (3m, 2H), 7.66-7.22 ( 3m, 2H), 6.35-6.20 (2m, ÍH), 5.86-5.56 (m, ÍH), 5.42-5.35 (m, 2H), 4.28-3.89 (m, 2H), 3.72-3.56 (m, 2H), 3.50-3.32 (m, ÍH), 3.27-3.14 (m, ÍH), 2.61-2.53 (4s, 3H); IR (KBr, cm "1) 3412, 2950, 1707, 1625, 1605 1481, 1464, 1385, 1324, 1198, 1086, 916, 764, 742; LCMS (-ESI, M-H") m / z 685.
Example 58: yellow-orange solid (mixture of diastereoisomers in sulfur): JH NMR at 500 MHz, (d6-DMSO, mixture of 2 diastereoisomers and rotamers) d 8.85-8.74 (m, 2H), 8.15-7.75 (, 2H) , 7.55-7.35 (, 2H), 6.45-6.10 (m, ÍH), 5.80-5.25 (m, 3H), 4.60-3.10 (m, 6H), 2.76, 2.74, 2.58 and 2.56 (all s, 3H); Negative ESI mass spectrum, m / e 568 (M-H) ".
Example 59
XH NMR at 300 MHz (CD3OD) d 8.87 (dd, ÍH, J = 9.6, 2.6 Hz), 8.78 (dd, ÍH, J-9.8, 2.6 Hz), 7.94 (dd, ÍH, J = 8.9, 4.4 Hz) , 7.83 (dd, ÍH, J = 9.0, 4.1 Hz), 7.38-7.27 (m, 2H), 6.14 (d, ÍH, J = 9.3 Hz), 4.34-4.18 (m, 2H), 3.94 (t, ÍH , J - 9.2 Hz), 3.73 (t, ÍH, J = 8.9 Hz), 3.51-3.22 (m, 4H). Negative ESI mass spectrum, m / e 596 (M-H) ".
Example 60: yellow solid, m.p. 228-232 ° C; NMR 1E (500 MHz, DMSO-de) 5 11.88 and 11.76 (2m wide, ÍH), 9.75-9.69 (2m, HH), 8.73-8.62 (2m, HH), 8.18 and 8.09 (2d, J = 4.8, 4.7 Hz, ÍH), 7.99-7.92 (2m, ÍH), 7.65-7.35 (m, 3H), 6.28 and 6.07 (2d, J = 8.9, 9.2 Hz, ÍH), 5.29-4.97 (3m, 3H), 4.10- 3.85 (3m, 2H), 3.60-3.48 (m, 2H), 2.97-2.70 (3m, 2H), 2.58 (m, 3H), 1.56-1.44 (m, 5H), 1.34 (m, 2H); IR (KBr, cm "1) 3406, 2934, 1705, 1622, 1481, 1461, 1430, 1374, 1321, 1284, 1179, 1081, 1038, 758, 747; MS (+ ESI, M + H *) m / z 590.
Example 61: yellow solid, m.p. 228-232 ° C; NMR * H
(500 MHz, DMSO-de) d 11.88 and 11.76 (2m wide, ÍH),
9. 75-9.69 (2m, ÍH), 8.73-8.62 (2m, ÍH), 8.18 and 8.09 (2d, J = 4.8, 4.7 Hz, ÍH), 7.99-7.92 (2m, ÍH), 7.65-7.35 (m, 3H ), 6.28 and 6.07 (2d, J = 8.9, 9.2 Hz, ÍH), 5.29-4.97 (3m, 3H), 4.10-3.85 (3m, 2H), 3.60-3.48 (, 2H), 2.97-2.70 (3m, 2H), 2.58 (m, 3H), 1.56-1.44 (m, 5H), 1.34 (, 2H); IR (KBr, cm "1) 3406, 2934, 1705, 1622, 1481, 1461, 1430, 1374, 1321, 1284, 1179, 1081, 1038, 758, 747; MS (+ ESI, M + H +) m / z 590.
Example 62: yellow solid, m.p. 280-282 ° C; NMR lE (500 MHz, DMSO-de) d 11.64 (broad s, ÍH), 9.83-9.68 (2m, ÍH), 9.08-8.97 (2m, ÍH), 8.45-7.10 (series of m, 8H), 6.37 and 6.25 (2d, J = 8.8, 9.1 Hz, HH), 5.74-5.68 (2m, HH), 5.50-5.21 (2m, 2H), 4.20-4.04 (2m, 4H), 3.71-3.60 (m, 2H); IR (KBr, cm'1) 3369, 2918, 1752, 1712, 1601, 1580, 1558, 1482, 1456, 1413, 1319, 1256, 1197, 1094, 1020, 914, 805, 762; MS (-ESI, M-H ") m / z 632.
Example 63: yellow solid, decomposition point 248 ° C; NMR 'H (500 MHz, DMSO-d6) d 11.65 (s broad H), 9.78-9.73 (2 m, H), 9.07-8.97 (2 m, H), 8.30-7.95 (m series, 3 H), 7.61- 7.42 (2m, 3H), 7.15-7.06 (m, 2H), 6.37 and 6.25 (d, J = 8.8, 9.3 Hz, ÍH), 5.81-5.22 (series of m, 3H), 4.32-4.12 (3m, 3H) ), 3.77, 3.63 (m, 3H); IR (KBr, cm "1) 3401, 2963, 1752, 1707, 1475, 1465, 1424, 1261, 1198, 1092, 1021, 801; LCMS (+ ESI, M + H +) m / z 650.
Example 64
Obtained 15.1 mg (49%), yellow solid, m.p. 254-265 ° C (decomposes); NMR XH (500 MHz, DMSO-d6) d 11.61 (broad s, ÍH), 9.76-9.66 (2m, ÍH), 9.01-8.92 (2m, ÍH), 8.31-7.96 (3m, 2H), 7.78 (s broad , ÍH), 7.58-7.45 (m, 2H), 6.30 and 6.19 (2d, J = 8.9, 9.4 Hz, ÍH), 5.99 (s broad, ÍH), 5.50-5.16 (series of, 3H), 4.12-3.92 (3m, 3H), 3.61-3.39 (, 3H); IR (KBr, c "1) 3392, 2927, 1706, 1661, 1604, 1567, 1532, 1480, 1463, 1384, 1324, 1085, 916, 826, 807, 764, 742; MS (-ESI, MH") m / z 649.
Example 65: yellow solid, m.p. 244-246 ° C; NMR XH (500 MHz, DMSO-dβ) d 11.63 (broad s, ÍH), 9.75-9.67 (2m, ÍH), 9.00-8.94 (2m, ÍH), 8.28-8.20 (2m, ÍH), 8.11-7.97 ( 2m, ÍH), 7.57-7.50 (m, 2H), 6.30 and 6.16 (2d, J = 8.8, 9.3 Hz, ÍH), 5.63-5.19 (series of m, 3H), 4.05-4.02 (m, ÍH), 3.61-3.07 (m, 6H); IR (KBr, cm "1) 3412, 1762, 1703, 1602, 1482, 1464, 1425, 1315, 1259, 1199, 1082, 916, 807, 763, 742; MS (-ESI, MH") m / z 637 .
Example 66: Obtained 4.7 mg (55%), yellow solid, m.p. 252-254 ° C (decomposes); NMR H (500 MHz, DMSO-dβ) d 11.60 (broad s, ÍH), 9.83-9.71 (2m, ÍH), 9.07, 9.01 (2m, ÍH), 8.30-8.07 (3m, 2H), 7.65-7.56 ( 2m, 2H), 6.43-6.30 (2m, 1H), 5.73-5.71 (m, 1H), 5.55-5.20 (2m, 2H), 4.21-4.07 (m, 4H), 3.81-3.52 (2m, 4H); IR (KBr, cm "1) 3384, 2926, 1706, 1622, 1602, 1568, 1482, 1464, 1426, 1384, 1309, 1259, 1230, 1081, 916, 805, 763, 742; LCMS (-ESI, MH ") m / z 653.
Example 67 Obtained 10.5 mg (26%), yellow solid, decomposition point 290 ° C; NMR 1E (500 MHz, DMS0-d6) d 12.34 and 12.23 (2s, ÍH), 11.58 (s, ÍH), 9.75-9.63 (2m, ÍH), 9.01-8.92 (2m, ÍH), 8.23-8.15 (m , ÍH), 8.17-7.96 (m, ÍH), 7.53-7.46 (m, 2H), 7.11-6.85 (series of m, 2H), 6.32 and 6.15 (2d, J = 8.9, 9.3 Hz, ÍH), 5.85 -5.14 (series of m, 3H), 4.11-3.98 (m, 2H), 3.71-3.49 (m, 4H); IR (KBr, cm "1) 3242, 2926, 1751, 1705, 1602, 1481, 1463, 1426, 1325, 1198, 1086, 915, 763, 742; MS (-ESI, M-H") m / z 621.
Example 71
2,3,9, 10-tetrafluoro-12- (4-deoxy-4,4-difluoro-b-D-glucopyranosyl) indole [2, 3-a] pyrrolo [2, 3-c] carbazole-5, 7-dione
To a solution of Dess-Martin periodinane (0.470 g, 1.11 mmol) in 30 ml of dichloromethane was added dropwise a solution of 6- (4-tert-butylbenzyl) -2,3,9,10-tetrafluoro-12 - (2,3,6-tri-0-benzyl-bD-glucopyranosyl) indole [2, 3-a] pyrrolo [3,4-c] -carbazole-5,7-dione (0.540 g, 0.55 mmol) in 20 ml of dichloromethane and the mixture was stirred at room temperature under argon atmosphere for 1 hour. Another 0.470 g (1.11 mmol) of the Dess-Martin reagent was added and stirring was continued for 2 hours. The resulting mixture was diluted with dichloromethane, washed (with saturated NaHCO3-Na2S203, saturated NaHC03, and brine), dried over sodium sulfate and evaporated. The residue was subjected to chromatography
(Si02 / hexane-ethyl acetate, 2: 1) to give the ketone (0.360 g, 67%) as a dark yellow solid.
To a portion of the ketone (0.067 g, 0.07 mmol) in 2 ml of dichloromethane was added DAST (0.036 ml, 0.28 mmol) and the mixture was stirred at room temperature under argon atmosphere for 18 hours. The mixture was then diluted with saturated sodium hydrogen carbonate solution in dichloromethane and the organic phase was separated, washed with brine, dried over sodium sulfate and evaporated to a gum. Flash chromatography (Si02 / hexane-ethyl acetate, 3: 1) gave 6- (4-tert-butylbenzyl) -2, 3, 9, 10-tetrafluoro-12- (4-deoxy-4, 4-difluoro -2, 3, 6-tri-O-benzyl-bD-glucopyranosyl) -indolo [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione as a yellow solid: 1H NMR (CDC13 , 400 MHz) d 10.21 (s, ÍH), 9.14 (dd, J = 10.6, 8.4 Hz, ÍH), 9.02 (dd, J = 10.7, 8.2 Hz, ÍH), 7.53 (d, J = 8.7 Hz, 2H ), 7.40 (d, J = 8.7 Hz, 2H), 7.34 (m, 5H), 7.20-7.12 (m, 6H), 6.97 (dd, J = 10.0, 6.6 Hz, ÍH), 6.80 (t, J = 7.4 Hz, HH), 6.72 (t, J = 7.6 Hz, 2H), 6.13 (d, J = 7.2 Hz, 2H), 5.82 (d, J = 8.6 Hz, HH), 4.97 (m, 3H), 4.80 (d, J = 11.1 Hz, ÍH), 4.65 and 4.61 (ab q, J = 12.0 Hz, 2H), 4.24-4.01 (m, 6H), 3.37 (d, J = 10.6 Hz, ÍH), 1.28 (s) , 9H). This material was deprotected in the usual manner (i) aqueous sodium hydroxide, tetrahydrofuran-ethanol, concentrated HCl, ii) ammonium acetate (NH4OAc), D, iii, H2, Pd (OH) 2-C, chloroform-methanol) to give the title compound (24% complete yield) as a yellow solid:
IR (KBr) 3410, 1747, 1704, 1596, 1478, 1323 cm "1; XH NMR (400 MHz, DMS0-d6) d 11.39 (s, ÍH), 11.34 (s, ÍH), 8.93 (, 2H), 8.03 (dd, J = 11.8, 6.8 Hz, ÍH),
7. 62 (dd, J = 10.7, 6.9 Hz, ÍH), 6.54 (d, J = 9.2 Hz, ÍH), 6.08 (m, 2H), 5.48 (d, J - 5.9 Hz, ÍH), 4.43 (m,
ÍH), 4.22 (m, ÍH), 4.06 (, 2H), 3.66 (m, ÍH). MS (ESI) m / e 578 (M-H). HPLC: 91.1% (320 nm).
Example 75: yellow solid: XH NMR at 500 MHz (d6-DMSO) d 11.85 (s, ÍH), 11.18 (s, ÍH), 8.92 (dd, ÍH), 8.81 (dd, ÍH), 8.06 (dd, ÍH) ), 7.78 (dd, ÍH), 7.49-7.39 (m, 2H), 6.28 (d, ÍH, l'H, J = 8.8 Hz), 5.85 (d, ÍH, 3'OH), 5.45 (d, ÍH) , 2'0H), 4.25-3.89 (m, 3H, 2'H, 3'H, 5'H), 3.68 (t, ÍH, 4'H), 1.42 (d, 3H, 6'H); ESI negative mass spectrum, m / e 531 (M-H). "IR (KBr) 2112 cm" 1.
Example 79
Yellow solid: NMR 'H at 500 MHz (d6-DMSO) d 12.72 (s, ÍH), 11.18 (s broad, ÍH), 8.92 (dd, ÍH), 8.80 (dd, ÍH), 8.21 (s broad, 2H ), 8.07 (dd, ÍH), 7.94 (dd, ÍH), 7.48-7.39 (m, 2H), 6.60 (d, ÍH, J = 7.8 Hz, l'H), 5.98 (s broad, ÍH, 3 ' OH), 5.48 (s broad, ÍH, 2'OH), 4.55-4.50 (m, ÍH, 5'H), 4.07-4.02 (m, 2H, 2'H, 3'H), 3.19 (t, ÍH , 4'H), 1.43 (d, 3H, 6'CH3); ESI negative mass spectrum 505 (M-H) ".
Example 87; yellow solid: NMR 'H at 300 MHz (CD3OD) d 8.84 (dd, ÍH), 8.74 (dd, ÍH), 7.77 (dd, ÍH), 7.35-7.24 (m, 2H), 6.14 (d, ÍH, J = 9.2 Hz), 4.23-3.95 (, 4H), 3.90 (t, 1H, J = 9.2 Hz), 3.74 (t, ÍH, J = 9.0 Hz); IR (KBr) 2114 cm "1; ESI negative mass spectrum, m / e 547 (M-H)".
Example 88: yellow solid 500 MHz XH NMR (CD30D) d 8.89 (dd, ÍH), 8.77 (dd, ÍH), 7.81 (dd, ÍH), 7.63 (dd, ÍH), 7.33-7.26 (m, 2H) , 6.15 (d, ÍH, J = 8.9 Hz), 4.24-3.88 (m, 3H), 3.73 (t, ÍH, J = 8.9 Hz), 3.59 (dd, ÍH, J = 9.6, 8.9 Hz), 3.54 ( t, ÍH, J = 9.6 Hz); Negative ESI mass spectrum, m / e 521 (M-H) ".
Example 89: yellow solid: IR (KBr) 3435, 3345, 1740, 1713, 1477, 1320 cm "1; NMR lE (THF-d8, 400 MHz) d 11.50 (s, ÍH), 10.12 (s, ÍH), 9.08 (dd, J = 11.0, 8.6 Hz, ÍH), 8.99 (dd, J = 11.0, 8.4 Hz, ÍH), 7.71 (dd, J - 11.5, 6.6 Hz, ÍH), 7.63 (dd, J = 10.3, 6.7 Hz), 6.11 (d, J = 8.9 Hz, HH), 5.30 (d, J = 4.5 Hz, HH), 5.01 (d, J = 4.1 Hz, HH), 4.62 (d, J = 5.1 Hz, HH ), 4.56 (d, J = 9.7 Hz, ÍH), 4.00 (s, 3H), 3.97-3.91 (, ÍH), 3.78-3.54 (m, 2H).
Example 90
3, 9-difluoro-12, 13-dihydro-13- (2-fluoro-bD-glucopyranosyl) -5 (H) indole [2, 3-a] pyrrolo [3, 4-c] -carbazole-5, 7 -Diona.
Using the Mitsunobu procedure described at the beginning in Example 22, 250 mg (0.465 mmol) of the product of Example 6 and 210 mg (0.464 mmol) of 2-fluoro-3,4,6-tri-O-benzyl were mixed. -D-glucopyranose (prepared by treating commercially available Tri-O-benzyl-D-glucal (1.5 g, 3.6 mmol) with xenon difluoride (1.0 g, 5.91 mmol) in acetonitrile (50 ml) and water (5 ml) ) for 3 hours at room temperature The typical work followed by flash chromatography on silica gel with 5% ethyl acetate in methylene chloride gave 380 mg (23.4%) of the 2-fluoro-3,4,6-tri -O-benzyl-D-glucopyranose This procedure was a modification of a published method: see T. Hayashi, BW Murray, R. Wang, and C.-H. Wong Bioorganic and Medicinal Chemistry, 1997, 5 497-500) . After purification by flash chromatography using 20-60% methylene chloride in hexane, 120 mg (28%) of the reasonably pure glycosylated product was obtained: the removal of the benzyl protecting groups by using the hydrogenation conditions of transfer (95% ethanol / cyclohexene / 20% Pd (OH) 2 / C, reflux for 6-48 hours) followed by removal of the 4-t-bitylbenzyl protecting group under basic hydrolysis conditions (potassium hydroxide 4.45) M, ethanol / reflux, concentrated hydrochloric acid, ammonium acetate / ethanol / heat for 8-48 hours) provided, after purification by flash chromatography on silica gel with acetone: methylene chloride: ethyl acetate, followed by Further purification on Sephadex LH-20 in methanol gave 15 mg (39% for the 2 unblocking steps) of the pure title compound as a yellow-orange solid: NMR: H at 300 MHz (d6-DMSO) d 11.68 ( s broad, ÍH), 11.28 (s broad, ÍH), 8.88 (dd, ÍH), 8.78 (dd, ÍH), 8.10 (dd, ÍH), 7.68 (dd, ÍH), 7.60-7.43 (, 2H), 6.77 (dd, ÍH, J = 8.8, 2.5 Hz), 6.23 (s broad, ÍH), 5.77 (s broad, ÍH), 5.62 (s broad, ÍH), 4.32 (dt, ÍH, J = 50.7, 9.0 Hz) 4.15-3.80 (m, 5H); ESI negative mass spectrum, m / e 524 (M-H) ".
Example 91
3, 9-di f luoro- 12- (ß-D-glucopyranosyl) benzofurane [2, 3-a] pyrrolo [3,4- c] carbazole-5, 7-dione Yellow solid IR (KBr) 1757, 1706 , 1483 cm "1 NMR? E (400 MHz, DMSO-d6) d 11.45 (broad s, HI),
8. 84-8.79 (m, ÍH), 8.53-8.46 (m, ÍH), 8.08-7.81 (m,
ÍH), 7.64-7.50 (m, 2H), 6.49 (d, 0.7 H, J = 8.9 Hz),
6. 07 (d, 0.3 H, J = 8.9 Hz), 5.38-5.16 (m, 3H), 4.75-4.21 (m, ÍH), 3.93-3.49 (m, 6H). HPLC: 97.5% (305 nm).
Example 92
3-bromo-9-fluoro-12- (β-D-glucopyranosyl) benzofuran- [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione Yellow solid IR (KBr) 1775, 1708 cm * 1 NMR aH (DMSO-d6, 400 MHz) 6 11.69 and 11.49 (broad 2s,
ÍH), 8.97 (d, 0.3H, J = 2.0 Hz), 8.91 (d, 0.7H, J = 2.0 Hz), 8.85-8.79 (m, ÍH), 8.08-7.77 (m, 3H), 7.59-7.49 (, ÍH), 6.47 (d, 0.7H, J = 9.0 Hz), 6.07 (d, 0.3H, J = 9.0 Hz), 5.37-5.21 (m, 3H), 4.79-4.20 (m, ÍH), 3.92 -3.54 (, 6H). HPLC: 92.5% (260 nm).
Example 93 3-cyano-9-fluoro-12- (β-D-glucopyranosyl) benzofuran- [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione
3-Bromo-9-fluoro-12- (2, 3, 4, 6-tetra-O-benzyl-β-D-glucopyranosyl) benzofuran [2,3-a] -pyrrolo [3,4-c] carbazole -5,7-dione (189 mg, 0.2 mmol) was combined with zinc cyanide (14 mg, 0.6 mmol) and tetrakis- (triphenylphosphine) palladium (0) (12 mg, 0.01 mmol) in deoxygenated dimethylformamide (2 mL) and the yellow suspension was heated at 80 ° C under nitrogen atmosphere for 16 hours. The mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and evaporated. The resulting residue was chromatographed (hexane: ethyl acetate, 7: 3) to give 3-cyano-9-fluoro-12 (2, 3, 4, 6-tetra-O-benzyl-β-D-glucopyranosyl) ) benzofuran [2, 3-a] pyrrolo [3,4-c] -carbazole-5, 7-dione (160 mg, 90%) as a yellow solid: IR (KBr) 2235 cm "1. To a solution of 3-cyano-9-fluoro-12- (2, 3, 4, 6-tetra-O-benzyl-β-D-glucopyranosyl) benzofuran [2, 3-a] pyrrolo [3, 4-c] -carbazole- 5,7-dione (58 mg, 0.06 mmol) in 5 ml of anhydrous methylene chloride was added dropwise boron trichloride (0.39 ml, 1.0 M solution in methylene chloride) at -78 ° C. The resulting solution it was warmed to 0 ° C and stirred for 2 hours and cooled again to -78 ° C before the addition of methanol (5 ml) This resulting mixture was warmed to room temperature The solvent was removed in vacuo and the The remaining residue was taken up in ethyl acetate / tetrahydrofuran and washed with 10% aqueous hydrochloric acid and brine before drying over sodium sulfate. Sodium and concentration of the solvent. Purification of the residue by preparative thin layer chromatography (THF: Hex, 9: 1) afforded the title compound (18 mg, 53%) as a yellow solid: IR (KBr) 3417, 2220, 1757, 1708, 1635, 1478 cm "1: XH NMR (DMSO-d6, 400 MHz) d 9.05 (s, 0.3H), 8.90 (s, 0.7H), 8.70-8.67 (, ÍH), 8.16-7.95 (m, 3H), 7.48 -7.45 (m, ÍH), 6.42 (d, 0.7H), J - 8.3 Hz), 6.11 (d, 0.3H, J = 8.3 Hz), 5.45-5.37 (m, 3H), 4.17-3.50 (7H) HPLC: 91.4% (260 nm).
Example 94
3-iodo-9-fluoro-12- (ß-D-glucopyranosyl) benzofuran- [2, 3-a] pyrrolo [3,4-c] carbazole-5, 7-dione
3-bromo-9-fluoro-12- (2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl) enzofuran [2, 3-a] -pyrrolo [3,4-c] carbazole -5,7-dione (189 mg, 0.2 mmol) was combined with bis (tributyltin) (0.2 mL, 0.4 mmol) and tetrakis- (triphenylphosphine) palladium (0) (23 mg, 0.02 mmol) in deoxygenated NMP (2 mL). ) and the yellow suspension was heated at 90 ° C under nitrogen atmosphere for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and evaporated. The resulting residue was chromatographed (hexane: ethyl acetate, 4: 1) to give 3-tributylstannyl-9-fluoro-12- (2, 3, 4, 6-tetra-O-benzyl-β-D- glucopyranosyl) benzofuran [2, 3-a] -pyrrolo [3,4-c] carbazole-5,7-dione (150 mg, 90%) as a yellow solid. To a solution of this yellow oil in 5 ml of methylene chloride was added iodine (33 mg, 0.13 mmol) and the mixture was stirred at room temperature for 0.5 hour). The resulting mixture was treated with saturated NaHS03, washed with water, brine, dried and evaporated. This crude residue (118 mg, 91%) was treated with boron trichloride (0.71 ml, 1.0 M solution in methylene chloride) as previously described to give the title compound as a yellow solid: IR
(KBr) 3140, 3040, 1753, 1703, 1405 cm "1: XH NMR
(exchange of DMSO-d6 and D20, 400 MHz) d 9.05 (d, 0.3H, J - 1.7 Hz), 8.89 (d, 0.7H, J = 1.7 Hz), 8.67
(dd, 0.3H, J = 9.5, 2.7 Hz), 8.62 (dd, 0.7H, J = 9.5, 2.7 Hz), 7.98-7.64 (m, 3H), 7.47-7.41 (m, ÍH), 6.42
(d, 0.7H, J = 9.0 Hz), 6.00 (d, 0.3H, J = 9.0 Hz), 4.26-3.50 (m, 6H): HPLC: 94.9% (320 nm).
Example 95
6- (4-tert-butylbenzyl) -2,3,9,10-tetrafluoro-12- (2, 3, 4, 6-tetra-O-benzyl-β-D-glucopyranosyl) indolo- [2, 3 a] pyrrolo [3, 4-c] carbazole-5, 7-dione
To a suspension of 6- (4-tert-butylbenzD-2,3,9, 10-tetrafluoroindolo [2,3-a] -pyrrol [3,4-c] carbazole-5,7-dione (1,131 g, 2.08 mmol) and anhydrous sodium sulfate (5.0 g) in 25 ml of anhydrous tetrahydrofuran was added finely powdered potassium hydroxide (0.932 g, 16.6 mmol).
The resulting mixture was stirred vigorously at room temperature under argon atmosphere for 1.5 hours. To the resulting dark purple mixture was added a solution of 2,3,4,6-tetra-0-benzyl-α-D-glucopyranosyl chloride (1450 g, 2.60 mmol) in 10 ml of anhydrous tetrahydrofuran and the stirring was continued for 24 hours. hours. An additional amount of 0.200 g (0.36 mmol) of chloro sugar was added and the stirring was continued for another 24 hours. The mixture was then diluted with ethyl acetate and quenched with 1N hydrochloric acid. The organic phase was separated, washed with brine, dried over sodium sulfate and evaporated to give a yellow foam. Flash chromatography (pre-adsorbed on silica (SiO2); eluted with hexane-ethyl acetate, 5: 1) gave the product as a bright yellow crystal. This crystal was taken up in dichloromethane and the solution was diluted with methanol. Concentration of this solution on the rotary evaporator, followed by vacuum drying, gave the title compound (1240 g, 54%) as a bright yellow solid: IR (KBr) 3307, 1748, 1694, 1593, 1473, 1072 cm. 1; H-NMR (CDC13, 400 MHz) d 10.58 (s, 1H), 9.18 (dd, J -10.7, 8.2 Hz, 1H), 9.07 (dd, J = 10.8, 8.2 Hz, ÍH), 7.53 (d, J - 8.3 Hz, 2H), 7.41 (m, 6H), 7.28 (m, 8H), 7.22 (, 4H), 6.94 (d, J - 10.1, 6.5 Hz, ÍH), 6.88 (t, J = 7.3 Hz , ÍH), 6.81 (t, J = 7.3 Hz, 2H), 6.16 (d, J = 7.2 Hz, 2H), 5.75 (d, J - 8.4 Hz, ÍH), 5.03 (d, J = 10.8 Hz, ÍH) ), 4.96 (m, 2H), 4.90 (m, 2H), 4.78 (d, J = 10.8 Hz, ÍH), 4.64 (d, J - 12.2 Hz, ÍH),
4. 58 (d, J = 12.2 Hz, ÍH), 4.29 (t, J = 10.4 Hz, ÍH),
4. 07 (d, J = 10.1 Hz, ÍH), 4.00-3.85 (m, 5H), 3.15 (d, J = 9.2 Hz, ÍH), 1.28 (s, 9H). Analysis Calculated for C65H55F4N3O: C, 73.22; H, 5.20; N, 3.94. Found: C, 72.92; H, 5.58; N,
4. 02.
Example 96
2,3,9,10-tetrafluoro-12- (β-D-glucopyranosyl) -indolo [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione IR (KBr) 3432, 3310 , 1743, 1702, 1475, 1331 cm "1; NMR aH (DMSO-dβ, 400 MHz) d 11.86 (s, ÍH), 11.31 (s, ÍH), 8.99 (dd, J = 11.1, 8.5 Hz, ÍH) , 8.92 (dd, J = 11.2, 8.3 Hz, ÍH), 8.18 (dd, J = 11.7, 6.9 Hz, ÍH),
7. 62 (dd, J = 11.0, 7.0 Hz, ÍH), 6.26 (d, J = 9.0 Hz, ÍH), 6.19 (t, J - 4.2 Hz, ÍH), 5.43 (d, J - 4.8 Hz, ÍH), 5.17 (d, J = 5.7 Hz, ÍH), 4.99 (d, J = 5.6 Hz, ÍH), 4.10 (dd, J - 10.7, 4.2 Hz, ÍH), 3.92 (m, 2H), 3.82 (m, ÍH) ), 3.57 (m, ÍH), 3.41 (m, ÍH). HPLC:
97. 1% (320 nm).
Example 97
2, 3, 9, 10-tetraf luoro-12- (6-f luoro-6-deoxy-β-D-glucopyranosyl) indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7 -dione IR (KBr) 3440, 3365, 1750, 1705, 1478 cm "1. XH NMR (DMSO-dβ, 400 MHz) d 12.04 (s, 0.5H), 11.31
(s, 0.5H), 11.27 (s, 0.5H), 10.68 (s, 0.5H), 9.07
(dd, J = 11.3, 8.8 Hz, 0.5H), 8.95 (dd, J = 19.4, 9.2
Hz, ÍH), 8.87 (dd, J = 10.9, 8.9 Hz, 0.5H), 8.17 (dd,
J = 11.9, 6.9 Hz, 0.5H), 7.91 (dd, J = 11.5, 7.1 Hz, 0.5H), 7.71 (dd, J - 10.7, 6.9 Hz, 0.5H), 7.50 (dd, J
= 9.6, 6.9 Hz, 0.5H), 6.34 (d, J = 8.8 Hz, 0.5H), 6.32 (d, J = 7.9 Hz, 0.5H), 5.98-4.73 (m, 5H), 4.22-3.46 (m , 4H). HPLC: 98.2% (320 nm).
'Example 98
6- (4-tert-butylbenzyl) -2,3,9, 10-tetrafluoro-12- (2,3,6-tri-O-benzyl-β-D-galactopyranosyl) indole [2, 3-a] - pyrrolo [3, 4-c] carbazole-5,7-dione
A solution of 6- (4-tert-butylbenzyl) -2,3,9,10-tetrafluoro-12- (2,3,6-tri-0-benzyl-4-0- (4-methoxybenzyl) -β) -D-galactopyranosyl) indole [2, 3-a] -pyrrolo [3,4-c] carbazole-5,7-dione (0.135 g, 0.12 mmol) in 10 ml of 10% trifluoroacetic acid-methylene chloride stirred at room temperature under argon atmosphere for 20 minutes. The resulting mixture was diluted with dichloromethane and then washed (saturated sodium hydrogen carbonate), dried over magnesium sulfate and evaporated. The resulting residue was subjected to chromatography (silica / ethyl acetate-hexane, 1: 2) to give the title compound (0.107 g, 90%) as a yellow solid: NMR, H (DMSO-dβ, 400 MHz) d 12.21 (s, ÍH), 9.00 (dd, J = 11.1, 8.4 Hz, ÍH), 8.90 (dd, J = 11.2, 8.4 Hz, ÍH), 8.11 (dd, J = 12.0, 6.9 Hz, ÍH), 7.61 -7.18 (m, 15H), 6.71 (t, J = 7.4 Hz, ÍH), 6.61 (t, J - 7.7 Hz, 2H), 6.39 (d, J = 9.2 Hz, ÍH), 6.18 (d, J = 7.2 Hz, 2H), 4.89 (s, 2H), 4.87 (d, J = 13.9 Hz, ÍH), 4.71 (d, J = 12.1 Hz, ÍH), 4.58 (s, ÍH), 4.49 (s, 2H) , 4.33 (m, ÍH), 4.20 (m, 2H), 4.00-3.66 (m, 4H), 3.58 (d, J = 11.2 Hz, ÍH), 1.26 (s, 9H).
Example 99
6- (4-tert-butylbenzyl) -2,3,9, 10-tetrafluoro-12- (2,3,6-tri-O-benzyl-4-deoxy-β-D-galactopyranosyl) indolo- [2, 3-a] pyrrolo [3, 4-c] carbazole-5, 7-dione
To a solution of 6- (4-tert-butylbenzyl) -2,3,9,10-tetrafluoro-12- (2,3,6-tri-O-benzyl-β-D-galactopyranosyl) indole [2, 3-a] pyrrolo [3, 4-c] carbazole-5,7-dione (0.402 g, 0.41 mmol) in 10 mL of acetonitrile was added DMAP (0.100 g, 0.82 mmol), followed by phenyl chlorothionoformate. (0.085 g, 0.49 mmol) and the mixture was heated to reflux under an argon atmosphere for 19 hours. An additional amount of 0.043 g (0.25 mmol) of phenyl chlorothionoformate and 0.030 g (0.25 mmol) of DMAP was then added, and the mixture was heated to reflux for 19 hours. The cooled mixture was partitioned with ethyl acetate and saturated sodium hydrogen carbonate and the organic phase was washed, dried and evaporated. The residue was subjected to flash chromatography (silica / ethyl acetate-hexane, 1: 3) to give the thionocarbonate (0.320 g, 0.29 mmol, 70%) as a solid. This material was dissolved in 10 ml of toluene, the solution was purged with a stream of argon bubbles for 15 minutes and then AIBN (0.010 g, 0.06 mmol) and tributyltin hydride (0.126 g, 0.43 mmol) were added. The resulting solution was heated to reflux under an argon atmosphere for 18 hours. Another 0.126 g of tributyltin hydride and 0.010 g of AIBN were added and the reflux was continued for 4 hours. The cooled mixture was evaporated and the residue was subjected to chromatography (silica / ethyl acetate-hexane, 1: 2) to give the title compound (0.215 g, 78%) as a yellow solid: IR cm "1; 2 H NMR (CDC13, 400 MHz) d 10.69 (s, ÍH), 9.15 (dd, J = 10.7, 8.4 Hz, ÍH), 9.06 (dd, J = 10.7, 8.3 Hz, ÍH), 7.53-7.24 (m, 15H) , 6.98 (dd, J = 10.1, 6.6 Hz, HH), 6.83 (m, HH), 6.78 (m, 2H), 6.18 (d, J = 7.0 Hz, 2H), 5.68 (d, J - 8.9 Hz, ÍH), 4.95-4.68 (m, 5H), 4.19-3.75 (m, 7H), 3.30 (d, J = 10.5 Hz, ÍH), 2.58 (m, ÍH), 2.35 (m, ÍH), 1.26 (s) , 9H).
Example 100
2,3,9, 10-tetrafluoro-12- (4-deoxy-β-D-glucopyranosyl) indole [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione IR (KBr) 3440, 1745, 1710, 1474 cm "1 NMR I (DMSO-dβ, 400 MHz) d 11.89 (s, ÍH), 11.31 (s, ÍH), 8.99 (dd, J-9.8, 8.9 Hz, ÍH), 8.92 (dd, J = 10.3, 9.0 Hz, HH), 8.14 (dd, J = 11.7, 6.5 Hz, HH), 7.64 (d, J = 10.5, 6.9 Hz, HH), 6.21 (t, J = 4.5 Hz , ÍH), 6.18 (d, J = 9.2 Hz, ÍH), 5.07 (d, J = 5.6 Hz, ÍH), 4.96 (d, J - 5.4 Hz, ÍH), 4.28 (d, J = 12.1 Hz, ÍH) ), 3.90-3.75 (m, 3H), 2.27 (m, HH), 2.01 (, ÍH), HPLC: 96.7% (320 nm).
Example 101 2,3,9,10-tetrafluoro-12- (2,3,4-tri-O-benzyl-β-D-glucopyranosyl) indole [2,3-a] pyrrolo [3,4-c] carbazole -5, 7-dione
A solution of 2, 3, 9, 10-tetraf luoro-12- (2,3,4-tri-0-benzyl-6-0- (-me tox ibenzyl) -β-D-glucopyranosyl) indole [2, 3-a] pyrrolo [3,4-c] carbazole-5,7-dione (0.410 g, 0.43 mmol) in 10 ml of 10% trifluoroacetic acid-methylene chloride was stirred at room temperature under an argon atmosphere for 15 minutes. minutes The resulting mixture was diluted with ethyl acetate (50 ml) and then washed (sodium acid carbonate), 2 x 50 ml; H20, 2 x 50 ml; brine, 50 ml) was dried over magnesium sulphate and evaporated. The resulting residue was subjected to chromatography (silica / 2-26% ethyl acetate-hexane) to provide the title compound (0.346 g, 97%) as a yellow solid: IR (CH2C12) 3333, 1753, 1700, 1478 1093 cm "1; NMR aH NMR (DMS0-d6, 400 MHz) d 11.76 (s, ÍH), 11.33 (s, ÍH), 8.99 (dd, J = 10.8, 8.5 Hz, ÍH), 8.93 (dd, J = 10.9, 8.5 Hz, ÍH), 8.14 (dd, J - 11.8, 6.8 Hz, ÍH), 7.66 (dd, J = 10.7, 6.9 Hz, ÍH), 7.40 (m, 5H), 7.26 (m, 5H ), 6.98 (t, J - 7.4 Hz, ÍH), 6.83 (t, J = 7.6 Hz, 2H), 6.55 (d, J = 8.9 Hz, ÍH), 6.44 (m, ÍH), 6.10 (d, J = 7.6 Hz, 2H), 4.96 (d, J = 11.1 Hz, ÍH), 4.92 (d, J = 11.0 Hz, ÍH), 4.82 (m, 2H), 4.23 (t, J = 9.4 Hz, ÍH), 4.20-4.06 (m, 3H), 3.98-3.95 (m, 2H), 3.66 (t, J = 9.0 Hz, ÍH), 2.94 (d, J - 10.6 Hz, ÍH), HPLC: 98.9% (320 nm) Analysis Calculated for C47H35F4N3? 7: C, 68.03; H, 4.25; N, 5.07. Found: C, 68.00; H, 4.72; N, 4.79.
Example 102
2,3,9, 10-tetrafluoro-12- ((2,3,4-tri-O-benzyl-β-D-glucopyranoside) uronate) indolo- [2,3-a] pyrrolo [3, 4-c] ] -carbazole-5, 7-dione
To a solution of 2, 3, 9, 10-tetrafluoro-12- (2, 3, -tril-O-benzyl-β-D-glucopyranosyl) indolo- [2, 3-a] pyrrolo [3, 4- c] carbazole-5,7-dione (0.125 g, 0.15 mmol) in 12 ml of anhydrous dimethylformamide was added pyridinium dichromate (PDC) (0.282 g, 0.75 mmol) and the mixture was stirred at room temperature for 4 hours. Then another 0.282 g (0.75 mmol) of PDC was added and the stirring was continued for 16 hours. An additional portion of PDC (0.282 g, 0.75 mmol) was added and this was repeated after 24 hours. A total of 1128 g (3.0 mmol) of PDC was added and the reaction was run for 4 days. The resulting mixture was cooled to 5 ° C, treated with 10 ml of saturated NaHS03 and then diluted with water (25 ml). This mixture was extracted with ethyl acetate-tetrahydrofuran (1: 1, 4 x 25 ml) and the combined extract was washed (2 x 25 ml of saturated NaHS03, and 25 ml of brine), dried over magnesium sulfate and dried. evaporated The resulting residue was subjected to chromatography (silica / 0-20% methanol-methylene chloride) to give the title compound (0.069 g, 55%) as a yellow solid: IR (KBr) 3412, 3260, 1746, 1710 , 1597, 1477, 1320 c "1; XH NMR (DMSO-de, 400 MHz) d 11.21 (s, ÍH), 9.02 (dd, J = 10.8, 8.8 Hz, ÍH), 8.57 (s broad, ÍH), 8.00 (m, HH), 7.85 (m, HH), 7.45 (d, J = 7.0 Hz, 2H), 7.33 (m, 3H), 7.19 (s, 5H), 7.00 (t, J - 7.4 Hz, 1H ), 6.86 (t, J = 7.5 Hz, 2H), 6.38 (d, J - 7.2 Hz, ÍH), 6.07 (d, J = 7.3 Hz, 2H), 4.93 (d, J = 10.8 Hz, ÍH), 4.77 (d, J = 11.2 Hz, ÍH), 4.73 (d, J = 10.8 Hz, ÍH), 4.64 (d, J = 11.2 Hz, HH), 4.29 (d, J = 8.8 Hz, HH), 4.04 ( m, ÍH), 3.89 (m, 2H), 3.35 (m, ÍH), 2.82 (m, ÍH).
Example 103
2,3,9, 10-tetrafluoro-12- [[(β-D-glucopyranoside) uronic acid] indole [2, 3-a] pyrrolo [3,4-c] -carbazole-5,7-dione
A mixture of 2, 3, 9, 10-tetrafluoro-12 - [(2, 3, 4-tri-O-benzyl-β-D-glucopyranoside) uronate] indolo was hydrogenated at 20 hours for an hour [2, 3 -a] -pyrrolo [3, 4-c] carbazole-5, 7-dione (0.030 g, 0.035 mmol) and 20% palladium hydroxide on mineral carbon (0.030 g) in a methanol mixture (5 ml) and tetrahydrofuran (5 ml). Another 30 mg of 20% palladium hydroxide was added over mineral coal and the hydrogenation was continued for another 24 hours. The resulting mixture was filtered, the filter cake was washed with tetrahydrofuran-methanol-water (10: 10: 1, 4 x 5 ml) and the filtrate was evaporated to give a solid residue. Flash chromatography (silica / 2-20% methanol-tetrahydrofuran and then 20% methanol-tetrahydrofuran containing 1-4% water) provided the title compound (0.006 g, 30%) as a yellow solid: IR ( KBr) 3425, 3260, 1740, 1707, 1600, 1475, 1322 cm "1; 1N-NMR (DMSO-dβ, 400 MHz) d 13.11 (s broad, ÍH), 10.96 (s broad, ÍH), 9.02-7.51 ( m, 5H), 6.21 (d, J = 8.9 Hz, ÍH), 5.4-4.0 (m, 8H).
Example 104
3-carboxy-9-f luoro-12- (β-D-glucopyranosyl) -benzofurano [2,3-a] pyrrolo [3,4-c] carbazole-5,7-dione
3-Cyano-9-fluoro-12- (2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl) benzo fu [2, 3-a] -pyrrolo [3, 4- c] carbazole-5,7-dione (380 mg, 0.43 mmol) in ethanol: tetrahydrofuran (10 ml: 5 ml) was added to a 4.0 M sodium hydroxide solution (10 ml). The mixture was refluxed gently for 24 hours. This resulting mixture was cooled to 0 ° C and treated with concentrated hydrochloric acid (15 ml). This solution was stirred at room temperature for 24 hours before it was taken up in ethyl acetate: tetrahydrofuran and washed with water and brine before drying and concentration of the solvent. To this residue was added solid ammonium acetate (5.0 g) and the mixture was melted at 150 ° C for 1 hour before it was cooled, diluted with ethyl acetate: tetrahydrofuran, washed with water, brine, dried on sodium sulfate and concentrated. A portion of this crude product (60 mg) was hydrogenated (Pd / C) as previously described to give the title compound (18 mg, 50%) as a yellow solid; IR (KBr) 3420, 1756, 1710, 1561, 1395 cm "1: NMR" H (exchange of DMS0-d6 and D20, 400 MHz) d 9.26 (s broad, ÍH), 8.83-8.76 (, ÍH), 8.22 (s broad, ÍH), 7.99-7.96 (m, ÍH), 7.83-7.68 (m, ÍH), 7.55-7.45 (m, ÍH), 6.51 (d, 0.6H, J = 8.9 Hz), 5.99 (d , 0.4H, J - 8.9 Hz), 4.31-3.43 (m, 6H): HPLC: 94.0% (320 nm).
Example 105
3, 9-difluoro-6 - [(2-guanidino-ethyl] -12, 13-dihydro-13- (bD-glucopyranosyl) -5 (H) indole [2, 3-a] pyrrolo [3, 4-c] ] -carbazole-5, 7-dione
To a magnetically stirred solution of the pure product of Example 10 (3.35 g, 3.25 mmol) in absolute ethanol (600 ml) was added aqueous potassium hydroxide (4.45 M, 60.0 ml, 267 mmol). The resulting dark red solution was heated in an open flask until about half of the ethanol was evaporated (approximately 3 hours). The mixture was cooled under a nitrogen atmosphere and concentrated hydrochloric acid (12 N, 175 ml) was added. The mixture was stirred 15 minutes and then partitioned with water (300 ml) and ethyl acetate (800 ml). The organic layer was washed with water (300 ml), with saturated aqueous sodium hydrogen carbonate solution (300 ml), and with brine (300 ml), dried over sodium sulfate and evaporated in vacuo. The resulting solid anhydride was treated with ethylenediamine (50 ml) and heated to boiling for about 4-5 hours, dissolved in absolute ethanol (175 ml), heated to reflux for about 6 hours, and then concentrated in vacuo. Purification by flash chromatography on silica gel with 2-10% methanol in methylene chloride gave 1.72 g (55%) of the pure 6N- (2-amino) ethyl derivative of the starting compound as a yellow-orange solid: NMR lE at 300 MHz (CDC13) d 10.65 (broad s, ÍH), 9.05 (dd, 1H), 8.94 (dd, ÍH), 7.55 (dd, ÍH), 7.45-7.14 (m, 18H), 7.00 (t , ÍH), 6.87 (t, 2H), 6.14 (d, 2H), 5.95 (d, ÍH), 5.05-4.58 (m, 6H), 4.40-4.34 (m, ÍH), 4.12-3.85 (m, 8H ), 3.22-3.15 (m, 2H), 2.96 (d, ÍH): ESI positive mass spectrum, m / e 927 (M + H) +. To a magnetically stirred solution of the pure product described above (1.72 g, 1.86 mmol) in anhydrous tetrahydrofuran (20 ml) was added N, N-diisopropylethylamine (314 ml), and N, N'-bis (benzyloxycarbonyl) -S-methylisothiourea (800 mg, 2.23 mmol: K. Nowak, L. Kania Rocz, Chem. 1969, 4_3 1953) and the reaction was heated in an oil bath at 70 ° C for 24 hours. The solution was cooled to room temperature, evaporated in vacuo, and purified by flash chromatography on silica gel using 5% ethyl acetate in methylene chloride to give 1.57 g (68%) of the pure guanidine derivative protected with di. -CBz of the initial amide, as a yellow solid: 1 H NMR at 300 MHz, (CDC13) d 11.80 (broad s, ÍH), 10.70 (broad s, ÍH), 9.18 (s broad, ÍH), 9.08 (dd, ÍH), 8.92 (dd, ÍH), 7.62-7.10 (m, 24H), 6.96 (t, ÍH), 6.85 (t, 2H), 6.13 (d, 2H), 5.95 (d, ÍH), 5.20-4.60 (m, 10H), 4.36 (t, ÍH), 4.20-3.85 (m, 10H), 3.02 (d, ÍH). To a solution of the product described above (1.58 g, 1.38 mmol) in methanol / ethyl acetate 3: 1 (120 ml) and IN hydrochloric acid (18 ml) under nitrogen atmosphere was added 20% palladium hydroxide (II) on carbon (722 mg). The mixture was placed on a Parr shaker under a hydrogen pressure of 4.57 kg / cm2 (65 psi) for 3 days, and then filtered through a small pad of Celite. The pad was washed with ethanol (3 x 50 ml) and concentrated in vacuo to give an orange solid. Purification on Sephadex LH-20 with elution with methanol gave 754 mg (91%) of the pure title compound as an orange-red solid: NMR: H at 500 MHz (CD3OD) d 8.83 (dd, 1H, J-9.7, 2.8 Hz), 8.73 (dd, ÍH, j = 8.9, 2.5 Hz), 7.77 (dd, ÍH, J = 9.2, 4.1 Hz), 7.63 (dd, ÍH, J - 8.9, 4.4 Hz), 7.34-7.25 (m , 2H), 6.15 (d, ÍH, J = 8.5 Hz), 4.32-4.17 (m, 2H), 4.11-3.97 (m, 2H), 3.91-3.84 (m, 2H), 3.78-3.66 (m, 2H) ), 3.60-3.53 (, 2H). Mass spectrum FAB, m / e 609 (M + H) *.
Example 106
2, 3, 9, 10-tetrafluoro-12- ((6-deoxy-6,6-difluoro-bD-glucopyranosyl) indole [2, 3-a] pyrrolo [3,4-c] carbazole-5,7- diona (R5, R5. = F, R2-R4 = OH, Xx, Xa-, X2, X2. = F, Q = NH)
A solution of 2, 3, 9, 10-tetrafluoro-12- (2, 3, 4-tri-O-benzyl-bD-glucopyranosyl) indole [2,3-a] -pyrrolo [3,4-c] carbazole -5,7-dione (0.166 g, 0.20 mmol) in 5 ml of dichloromethane was added to a cold solution (5 ° C) of the Dess-Martin periodinane (0.106 g, 0.25 mmol) in 5 ml of dichloromethane. The resulting mixture was stirred at room temperature under an argon atmosphere for 2 hours. The reaction mixture was subsequently diluted with ethyl acetate (25 ml), washed (sodium acid carbonate 1M-30% Na2S203, 2 x 10 ml; sodium carbonate acid sodium, 2 x 10 ml; water, 10 ml; brine, 10 ml), dried over magnesium sulfate and evaporated. The resulting residue was subjected to chromatography (silica / 2-30% ethyl acetate-hexane) to give 2,3,9,10-tetrafluoro-12- ((2,3,4-tri-O-benzyl) bD-glucopyranoside) uronaldehyde) indole [2, 3-a] pyrrolo [3,4-c] carbazole-5,7-dione (0.118 g, 71%) as a pale yellow solid: IR (CH2C12), 3344, 2930 , 1753, 1724, 1597, 1479, 1322 cm "1; XH NMR (CDC13, 400 MHz) d 11.08 (s, 0.3H), 10.68 (s, ÍH), 3.85 (s, 0.3H), 8.97 (m, 0.3H), 8.79 (m, 0.3H), 8.43 (m, ÍH), 7.99 (s broad, 0.7H), 7.83 (m, ÍH), 7.68 (m, 0.3H), 7.53-6.73 (, 14H) , 6.27 (m, 1H), 6.05 (d, J = 7.2 Hz, 2H), 5.80 (d, J = 9.0 Hz, ÍH), 5.61 (s, 2H), 5.09 (d, J = 11.1 Hz, ÍH) , 4.91 (m, 3H), 4.29-3.85 (m, 4H), 3.74 (t, J = 8.8 Hz, ÍH), 2.92 (d, J = 10.3 Hz, ÍH) To a cold solution (5 ° C) of the aldehyde (0.053 g, 0.085 mmol) in 5 ml of dichloromethane under argon atmosphere was added DAST (0.022 ml, 0.17 mmol) dropwise The resulting mixture was stirred at room temperature for 18 hours. The reaction was then diluted with ethyl acetate (20 ml), washed (1 M sodium hydrogen carbonate, 2 x 10 ml; water, 2 x 10 ml; brine, 10 ml), dried over magnesium sulfate and evaporated. The residue was subjected to chromatography (silica / 2-24% ethyl acetate-hexane) to give 2, 3, 9, 10-tetrafluoro-12- (2, 3, -tri-0-benzyl-6-deoxy). 6,6-difluoro-bD-glucopyranosyl) indole [2, 3-a] pyrrolo [3,4-c] carbazole-5,7-dione (0.046 g, 85%) as a pale yellow solid: IR (CH2C12) , 3400, 1757, 1728, 1596, 1478, 1320 cm "1; NMR lE (CDC13, 400 MHz) d 9.98 (s, ÍH), 8.89 (m, 2H), 7.71 (m, ÍH), 7.51-7.26 ( m, 11H), 7.09 (m, ÍH), 7.00 (t, J = 7.4 Hz, ÍH), 6.85 (t, J = 7.5 Hz, 2H), 6.24 (t, J = 53.7 Hz, ÍH), 6.13 ( d, J = 7.2 Hz, 2H), 5.80 (d, J = 9.0 Hz, ÍH), 5.04 (d, J = 11.2 Hz, HH), 4.89 (s, 2H), 4.84 (d, J = 11.2 Hz, ÍH), 4.23 (m, ÍH), 4.3 (m, 2H), 3.95 (d, J = 10.3 Hz, ÍH), 3.81 (m, ÍH), 3.04 (m, ÍH), MS (ESI) m / e 848 (MH) A mixture of tri-O-benzylglucopyranoside
(0.035 g, 0.041 mmol) and 20% Pd (OH) 2-C in a mixture of methanol (5 ml) and chloroform (2 ml) was hydrogenated under pressure of 1 atmosphere for 16 hours. The resulting mixture was filtered and the cake of the filtrate was washed with tetrahydrofuran-methanol (1: 1). The filtrate was evaporated and the residue was subjected to chromatography (silica / 2-12% methanol-methylene chloride) to give the title compound (0.019 g,
80%) as a yellow solid: IR (KBr) 3385, 1748, 1713, 1595, 1476, 1326 crn "1; NMR: H (THF-dβ, 400 MHz) d 10.55 (s, ÍH), 10-18 ( s-ÍH), 9.14 (dd, J - 10.6, 8.8 Hz, ÍH), 9.04 (dd, J = 10.6, 8.6 Hz, ÍH), 7.79 (dd, J = 11.5, 6.6 Hz, ÍH), 7.44 (dd , J - 9.8, 7.1 Hz, ÍH), 6.56 (t, J - 53.7 Hz, ÍH), 6.18 (d, J = 7.9 Hz, ÍH), 5.52 (s broad, ÍH), 5-10 (s broad, ÍH), 4.71 (s broad, ÍH), 4.27 (m, ÍH), 3.95 (m, ÍH), 3.69 (, 2H), HPLC: 95.2% (230 nm).
It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (17)
1. A compound of formula I, or a pharmaceutically acceptable salt thereof characterized in that Ri and Ria are independently hydrogen, a pentose group (A) or a hexose group (B) of the formulas B with the proviso that one of Ri and R? A is hydrogen and the other is not hydrogen; R2, R3, R4. Rs and R2"R R3 'R4' / 5" and 5 'are independently hydrogen, alkyl of 1 to 7 carbon atoms, cycloalkyl of 1 to 7 carbon atoms, 0, azido, halogen, NR9R? 0, NHC (0) ) NR9R10, NHC (0) 0R, OR, -C (0) Ra, SR, -0S02Rc, or together form = N-0H, = 0, = NR, with the proviso that R2, R3, R4, R5 and R2-R3., R4., R5", and R5 'are not all simultaneously hydrogen, OH, alkoxy or alkyl, and with the proviso further that R3 or R3 > is not -NH2, except when Rβ is - (CH2) nNHC (= NH) NH2, said alkyl of 1 to 7 carbon atoms is optionally substituted with one to six of the same or different substituents halogen, CN, N02, aryl or heteroaryl, the aryl or heteroaryl substituted with one or two groups independently selected from NR9R10, OH, COORg, Ra is H, OH, alkoxy of 1 to 7 carbon atoms or NRqR10; Rc is alkyl of 1 to 7 carbon atoms or aryl; R and Ru are independently hydrogen, alkyl of 1 to 7 carbon atoms, cycloalkyl of 1 to 7 carbon atoms, heteroaryl, ring of 5 to 8 membered cyclic, non-aromatic, containing either one or two heteroatoms selected from oxygen or nitrogen, (CH2) nNR9R10, (CH2) nOR9 or (CH2) nCOOR9, the alkyl of 1 to 7 carbon atoms is optionally substituted with one to six of the same or different halogen, OH, CN, N02, aryl or heteroaryl substituents , the aryl or the heteroaryl are substituted with one or two groups independently selected from NR9R10, OH, COOR9, SO3R9 or OCOR9; Rg and Rio are independently hydrogen, alkyl of 1 to 7 carbon atoms, cycloalkyl of 1 to 7 carbon atoms, benzyl, aryl, heteroaryl, any of which groups except hydrogen can be substituted with one to six of the same or different substituents halogen, OH, NH2, CN, N02, -C (= NH) NH2, -CH (-NH), CH (Rb) (CH2) nCOOH or CH (Rb) (CH2) nNH2 O COORn, OR R9 and R10 together with the nitrogen atom to which they join, they form a cyclic 5- to 8-membered non-aromatic ring containing either one or two heteroatoms of oxygen, nitrogen or sulfur, or Rg and Rio together form = CHRRn. Rb is H or COOH; Rβ is hydrogen, alkyl of 1 to 7 carbon atoms, aryl, arylalkyl, OR10, NR9R10, or OCO (CH2) nNR9R? 0, alkyl of 1 to 7 carbon atoms is optionally substituted with one to six thereof or different halogen substituents, NR9R? 0, CN, N02, aryl, the aryl is substituted with one or two groups independently selected from NR9R10, OH, COORg, R7 and R? are independently OH or hydrogen, or taken together is oxygen; Xi, X'i, X2 and X'2 are independently hydrogen, halogen, OH, -CN, -NC, CF3, -CORa, N02, OR, 0 (CH2) nNR9R? Or 0 (CH2) nORg or 0 (CH2 ) nCOOR9, * with the proviso that X2, X'2, Xi and X'i are not 1,11-dichlor; with the additional proviso that when X2 and X'2 are each hydrogen, Xi and X'i are each independently hydrogen or halogen, Rx is hexose, R7 and Re together are oxygen, and each of R2, R5, and R4 are OH, R2. , R3. , R4., And R5. and R5-are each hydrogen, Q is NH, and then each of R3 and R4 are not NH2 and R3 is not methoxy when Re is hydrogen; W is carbon or nitrogen; Q is oxygen, NR9, sulfur or CH2; and n is an integer from 0 to 4.
2. A compound according to claim 1, characterized in that in Ri or R? A all substituents are hydrogen, except R2, R3 and R4 which are each OH; and R5 is NR9R10.
3. A compound according to claim 1, characterized in that in Ri or R? A all substituents are hydrogen, except R2, R3 and R5 are each OH; and R4 is NR9R10.
4. A compound according to claim 1, characterized in that in Ri or Ria all substituents are hydrogen, except R2, R3 and R4 are each OH; and R5 is halogen.
5. A compound according to claim 1, characterized in that R7 and Rβ taken together is oxygen.
6. A compound according to claim 1, characterized in that:? , X'i, X2 and X'2 are independently halogen.
7. A compound according to claim 1, characterized in that the halogen group is fluoro.
8. A compound according to claim 1, characterized in that Q is 0, S or NH.
9. A compound according to claim 1, characterized in that R2, R3, and R5 are each OH; and R4 is NR9R10, halogen or N3.
10. A compound according to claim 1, characterized in that in Ri or R? A all substituents are H except R5, R3 and R4 are each OH; and R2 is halogen.
11. A compound according to claim 1, characterized in that in Ri or R? A all substituents are H except R2, R3 are each OH; R5 is halogen; and R4 is azido, NRgRX0 or OR.
12. A compound according to claim 1, characterized in that in Rx or R? A all substituents are H except R2, R3 are each OH; and R5 is halogen; and R is halogen, H or alkyl.
13. A compound according to claim 1, characterized in that in R: or R? A all substituents are H except R2 and R3 are each hydrogen or hydroxyl; R 4 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R5 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R? 0.
14. A compound according to claim 1, characterized in that in Ri or R? A all substituents are H except R3 and R4 are each hydrogen or hydroxyl; R 2 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and Ri is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R? 0.
15. A compound according to claim 1, characterized in that in Ri or R? A all substituents are H except R3 and R5 are each hydrogen or hydroxyl; and R2 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms; and R is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R? 0.
16. A compound according to claim 1, characterized in that in Ri or R? A all substituents are H except R2 and R are each hydrogen or hydroxyl; R3 is hydrogen, halogen, alkyl of 1 to 7 carbon atoms or azido; and R5 is hydroxyl, azido, alkyl of 1 to 7 carbon atoms, halogen or NR9R10.
17. A pharmaceutical formulation characterized in that it comprises an effective anti-tumor amount of a compound of the formula I, according to any of claims 1 to 16.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/024,657 | 1996-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99001454A true MXPA99001454A (en) | 2002-03-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0971717B1 (en) | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles | |
US6677450B2 (en) | Topoisomerase inhibitors | |
KR850001952B1 (en) | C-20-modified macrolide derivatives | |
MXPA99001454A (en) | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles | |
US7138377B2 (en) | Topoisomerase inhibitors | |
JP3264926B2 (en) | 3,4'-dideoxymycaminosyltylonolide derivative and method for producing the same | |
US6610727B2 (en) | Anhydro sugar derivatives of indolocarbazoles | |
CZ54999A3 (en) | Cytotoxic aminosaccharide and related saccharide derivatives of indolopyrrolocarbazoles | |
US6340670B1 (en) | Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation | |
EP1133509A1 (en) | Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation | |
KR20030085035A (en) | Topoisomerase I Selective Cytotoxic Sugar Derivatives of Indolopyrrolocarbazoles | |
JPS61225194A (en) | Novel compound, manufacture and medicinal composition | |
MXPA01005176A (en) | Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation | |
NZ611653A (en) | Ketolide compounds |